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1 LIST OF ABBREVIATIONS IN ALPHABETICAL ORDER 
α-SMA α-smooth muscle actin 
ALT alanine transaminase 
AP alkaline phosphatase 
AST aspartate transaminase 
Bcl-2 B-cell lymphoma 
cAMP cyclic adenosine monophosphate 
CCA cholangiocellular carcinoma 
ChIP chromatin immunoprecipitation 
CIT cold ischemic time 
CK7 cytokeratin 7 
DHH desert hedgehog 
DMEM Dulbecco's modified Eagle Medium 
ELISA enzyme-linked immunosorbent assay 
EPO erythropoietin 
ErbB-2 erythroblastic leukemia viral oncogene homolog 
GFP green fluorescent protein 
GLDH glutamate dehydrogenase 
GLI glioma-associated oncogene 
HCC hepatocellular carcinoma 
Hh hedgehog 
HIP hedgehog-interacting protein 
HSC hepatic stellate cells 
HTK histidine-tryptophan-ketoglutarate 
IHH indian hedgehog 
INR international normalized ratio 
LBWR liver body weight ratio 
LDH lactate dehydrogenase 
LDLT living donor liver transplantation 
LTx liver transplantation 
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MAPK mitogen-activated protein kinase 
MBF myofibroblast 
Mcl-1 myeloid cell leukemia-1 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PH partial hepatectomy 
PKA cAMP-dependent protein kinase 
PLK polo-like kinases 
pLTx 30% partial liver transplantation 
PT prothrombin time 
PTCH1 patched1 
PTT prothrombin time 
RBC red blood cells 
RFU relative fluorescence unit 
RT room temperature 
RT-PCR real time polymerase chain reaction 
SHH sonic hedgehog 
shRNA short hairpin RNA 
sLTx split liver transplantation 
SMO smoothened 
TIRF total internal reflection fluorescence 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
VEGF vascular endothelial growth factor 
WIT warm ischemic time 
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2 INTRODUCTION 
Liver transplantation (LTx) is a viable treatment option for acute liver failure and various end-
stage liver diseases including malignancies like hepatocellular carcinoma (HCC) and 
cholangiocellular carcinoma (CCA). The present work will focus on the development of 
accompanying mechanistic therapies that may be eligible for optimization of this lifesaving 
surgical procedure. The studies are divided into general optimization approaches of LTx and 
disease-specific mechanistic experiments aiming to identify suitable targets in order to improve 
LTx for unresectable CCA patients according to the multimodal therapy concept of the Mayo 
protocol.1 
 
2.1 General Optimization Approaches For Liver Transplantation 
In these experiments we sought to minimize liver preservation injury and improve 
microcirculation in implanted liver grafts by modification of a histidine-tryptophan-
ketoglutarate (HTK)-based preservation solution. In addition, we tested the effect of the 
pleiotropic substance erythropoietin (EPO) on liver regeneration/donor liver growth and 
hepatocyte apoptosis (programmed cell death) in the setting of partial liver transplantation 
(pLTx). 
 
2.1.1 Preservation solutions and the effect of chloride 
Preservation injury is still a major concern in liver transplantation, especially for grafts obtained 
from “extended criteria donors”.2-4 Preservation injury can be regarded as a consequence of 
hypoxia,5-8 injury triggered by hypothermia,7, 9, 10 a certain toxicity of the preservation 
solutions,11, 12 and at a later stage, inflammatory processes.7, 13, 14 Taking into account new 
findings on the mechanisms of the initial processes already occurring during cold  
preservation, we developed a new preservation solution on the basis of HTK solution (for 
composition see Table 1), which, in a preliminary (chloride-poor) version, was already shown  
to reduce preservation injury to isolated perfused rat livers in comparison with HTK solution.15 
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Table 1.   Compositions of HTK solution and the modified HTK solutions. To obtain a chloride-containing 
variant of the new solution, further but slight modifications became necessary for reasons of charge and osmolarity; 
these modifications mainly affected the concentrations of N-acetylhistidine (partly anionic), histidine (partly 
cationic), and sucrose. 
 
 
In the course of the mechanistic studies that formed the basis for developing the new 
preservation solution, we have described the entity of cold-induced apoptosis, an injury that 
affects numerous mammalian cell types such as rat hepatocytes, rat liver endothelial cells, rat 
renal tubular cells, rat coronary endothelial cells, porcine aortic endothelial cells, porcine 
corneal endothelial cells, and human umbilical vein endothelial cells.7, 9, 16-19 In all these cell 
types chelatable, ‘‘redox-active’’ iron plays the major role in the development of cold-induced 
apoptosis.7, 9, 16-21 
However, hepatocytes appear to be slightly different since in these cells iron chelators only 
provide partial protection from cold-induced injury during rewarming after cold incubation in 
cell culture medium or Krebs-Henseleit buffer.18, 19, 21 We further characterized this iron-
independent weaker cold-induced injury to rat hepatocytes and found it to be dependent on 
extracellular chloride.22 
In contrast to that, a another study on cold-induced injury to the endothelium of intact porcine 
aortic segments exhibited beneficial effects of chloride-containing preservation solutions on 
endothelial cell survival.23 This is in line with other experiments in cultured porcine 
aortic endothelial cells revealing strong adverse effects of chloride-poor preservation 
solutions.24 
As it was impossible to judge from these contradictory in vitro experiments which of the 
chloride-dependent effects has a higher biological relevance regarding the intact liver, we here 
tested a chloride-poor versus a chloride-containing variant of the new preservation solution in 
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an orthotopic rat liver transplantation model. Three different post-LTx survival series were 
performed since survival represents the study criterion with the highest medical relevance and 
since the clarification of the conflicting in vitro data is crucial for the further development of 
the preservation solution. The three series were designed to cover different balances of cold 
ischemic and warm ischemic injury as well as surgical trauma, thereby reflecting the broad 
range of potential clinical settings most closely. In addition, one LTx series (with intermediate 
cold and warm ischemic times [CIT/WIT]) was performed for assessment of 
intrahepatic microcirculation after reperfusion, laboratory data, bile production, and liver 
histology. 
 
2.1.2 Erythropoietin and liver regeneration/apoptosis 
After pLTx (or extended liver resection), efficient regeneration of the liver is essential for the 
clinical outcome. Especially after living donor liver transplantations (LDLT) and split liver 
transplantations (sLTx), which have been an important developments to overcome the growing 
problem of organ shortage,25 an immediate regeneration is most desirable because of the graft’s 
smaller size and its reduced functional liver mass. A small-for-size graft may not only be 
functionally insufficient for the recipient, but will also sustain injury characterized by rejection 
and ischemic insult, which results in an inadequate regeneration and leads to hepatic failure.26 
For the LDLT donor, an adequate regenerative response is of comparable importance. 
Unfortunately, more than 16% of all LDLT can not be performed, since the suggested 
graft/recipient- and remnant liver/donor-ratio of at least 0.8% can not be achieved.27 
Therefore, improvement of the regenerative capacity is of fundamental importance and novel 
therapeutic approaches are needed to optimize liver regeneration in the setting of LDLT/sLTx. 
Previously, we were able to demonstrate the positive effects of vascular endothelial growth 
factor (VEGF) as well as tri-iodothyronine as stimulators of liver regeneration after partial 
hepatectomy (PH). However, none of the above mentioned treatment strategies have proven 
definitive.28, 29 
EPO is a low molecular weight glycoprotein hormone stimulator of erythropoiesis produced in 
the fetal liver and subsequently in the adult kidney.30, 31 Stimulation of erythropoiesis was 
considered to be the sole physiological action of EPO, but there is increasing evidence 
suggesting a wider biological role including angiogenesis and liver regeneration.32, 33 Regarding 
the latter aspect it is known that not only the fetal but also the adult liver can be an extrarenal 
source of EPO.34 Indeed, in liver regeneration an increased synthesis of EPO has been 
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described, whereas enhanced EPO serum levels correlate with the peak of liver regeneration 
after PH.35 Here, the synthesis of EPO is mediated by erythropoietic hepatic factors 36, 37 and 
occurs in Kupffer cells 38-40 as well as erythroblastic islets within the liver lobules.37, 41 EPO 
was also reported as a stimulator of liver regeneration after PH in rats and pigs.32, 33 
 
2.2 Optimization Of Liver Transplantation For Cholangiocarcinoma 
Sole LTx for unresectable CCA is often associated with early disease relapse and limited overall 
survival.1 However, a small percentage of patients have achieved prolonged survival after LTx, 
suggesting that adjuvant approaches might improve the clinical outcome.1 Thus, a multimodal 
therapy protocol was developed at the Mayo Clinic, Rochester, Minnesota, USA employing 
pre-LTx external-beam irradiation, chemotherapy, and iridium brachytherapy for patients with 
unresectable CCA above the cystic duct and without extrahepatic metastases.1 After 
pretreatment and before LTx, patients undergo an exploratory laparotomy to exclude metastatic 
disease. The Mayo protocol has been proven to be quite successful for the treatment of patients 
with unresectable early-stage CCA.1  
However, employing the conventional chemotherapeutic agents fluorouracil and capecitabine, 
this protocol does not consider new mechanistic findings on CCA tumor biology and, thus, 
might be improvable by the implementation of „targeted chemotherapy”. The present CCA-
specific LTx optimization experiments aim to identify mechanistic processes underlying the 
pronounced resistance to apoptotic cell death characteristic for CCA cells. Based on these 
findings, new mechanistic therapy approaches were tested. 
 
2.2.1 The roles of myofibroblast derived growth factors and hedgehog signaling 
CCA is a highly lethal malignancy with limited treatment options.42-44 It is the most common 
biliary cancer and epidemiologic studies suggest that its incidence is increasing in several 
Western Countries.45 Human CCA in vivo paradoxically expresses the death ligand tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and its cognate death receptors 46 
suggesting that these cancers are reliant on potent survival signals for tumor maintenance and 
to circumvent apoptotic cell death by TRAIL. However, the mechanisms by which CCA evades 
apoptosis by TRAIL and other pro-apoptotic stimuli are incompletely understood. 
CCAs are highly desmoplastic cancers suggesting cancer-associated fibroblasts within the tumor 
microenvironment contribute to their development and progression as has been proposed for other 
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cancers (e.g. breast cancer, prostate cancer, etc.).47, 48 Cancer-associated fibroblasts are 
perpetually “activated” and express α-smooth muscle actin (α-SMA); cells exhibiting this 
activated phenotype are often referred to as myofibroblasts (MFBs).49 In the liver, MFBs are 
derived from periportal fibroblasts, hepatic stellate cells (HSCs), and perhaps an epithelial-to-
mesenchymal transition of cholangiocytes, hepatocytes, and/or the tumor itself.50, 51 A role for 
MFBs in carcinogenesis and tumor biology receives increasing attention.49, 52-54 Cross-talk 
between the cancer and MFBs appears to be exploited by cancer cells as a tumor promoting 
mechanism. For example, in CCA the number of MFBs correlates with tumor size and patient 
survival.55, 56 MFBs also appear capable of providing survival signals as they reduce apoptosis of 
non-malignant cholangiocytes in co-culture experiments.57 However, information regarding the 
nature of this cross-talk, and in particular the identity of the potential survival signals, remains 
obscure.  
Growth factor and especially platelet-derived growth factor (PDGF) paracrine signaling 
between MFBs and cholangiocytes occurs in rodent models of biliary tract inflammation and 
fibrogenesis.57, 58 Five different ligands of PDGF exist including PDGF-AA, -BB, -AB, -C and 
–D. However, PDGF-BB appears to be the predominant isoform secreted by liver MFBs.59 Of 
the two cognate receptors, platelet-derived growth factor receptor (PDGFR)-α and –β, PDGFR-
β is the cognate receptor for PDGF-BB. PDGFR-β is a receptor tyrosine kinase that is also 
known to alter plasma membrane dynamics associated with cell migration by a cyclic adenosine 
monophosphate (cAMP)-dependent kinase (PKA)-dependent process.60 Thus, PDGF-BB 
effects on intracellular signaling cascades are pleiotropic. Given an emerging role for PDGF-
BB in MFB-to-cholangiocyte cross-talk, a role for PDGF-BB as a survival factor for CCA 
warrants further investigation.  
The Hedgehog (Hh) signaling pathway has been strongly implicated in gastrointestinal tumor 
biology including CCA.61, 62 Hh signaling is initiated by any of the three ligands Sonic (SHH), 
Indian (IHH), and Desert (DHH) hedgehog. These ligands bind to the Hh receptor Patched1 
(PTCH1) resulting in activation of Smoothened (SMO) and subsequently the transcription 
factors glioma-associated oncogene (GLI) 1, 2, and 3.63 How PTCH1 modulates SMO was long 
enigmatic, as the two proteins do not physically associate. SMO trafficking from an intracellular 
compartment to the plasma membrane apparently results in its activation.64 Hh ligand binding 
to PTCH1 increases the concentration of intracellular messengers (lipid phosphates), which in 
turn promote SMO trafficking to the plasma membrane.65, 66 PKA affects SMO trafficking and 
activation, raising the unexplored possibility that cues from other ligand-receptor systems such 
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as PDGF-BB may also augment SMO activation by facilitating its trafficking to the plasma 
membrane.64  
Interestingly, SHH mRNA expression is increased by PDGF-BB in immature cholangiocytes58 
providing an additional link between Hh signaling and PDGF. Hh signaling also is a master 
switch mediating resistance of CCA cells to TRAIL cytotoxicity. 67, 68 Taken together, these 
observations suggest MFB-derived PDGF-BB may modulate Hh survival signaling in CCA 
cells. 
 
2.2.2 Interactions between hedgehog signaling and polo-like kinase 2 
As mentioned above, Hh signaling was reported to be an important survival pathway in CCA.67, 
69, 70 Hh ligand SHH is abundantly expressed in CCA cells, 69, 71 and in a recent mRNA 
expression analysis employing CCA cells, Hh signaling was suggested to positively regulate 
the cell division modulating enzyme kinase polo-like kinase 2 (PLK2).69  
PLK2 (or SNK) is one out of five mammalian PLK family members that orchestrate a wide 
range of critical cell cycle events.72-74 Besides PLK2, PLK1 (or STPK13), PLK3 (or CNK, FNK 
and PRK), PLK4 (or SAK and STK18) and PLK5 have been identified.73, 74 All PLK proteins 
share a similar structure with a canonical serine/threonine kinase domain at the N-terminus and 
a regulatory polo-box domain at the C-terminus 72; however, PLK4 has a notably divergent 
structure as compared to other PLK proteins and PLK5 as it lacks kinase activity. 73, 74  
About 80% of human cancers express high levels of PLK transcripts in tumor cells (these PLK 
transcripts are mostly absent in surrounding healthy tissues) and PLK overexpression is often 
associated with poor prognosis and lower overall survival.75 While PLK1 has been extensively 
studied and has become an attractive candidate for anti-cancer drug development, the roles of 
the other PLK proteins including PLK2 are less well understood.74  
PLK inhibition in esophageal squamous cell carcinoma and osteosarcoma was reported to 
decrease protein levels of myeloid cell leukemia-1 (Mcl-1).76, 77 This is of particular interest as 
Mcl-1, a potent anti-apoptotic member of the B-cell lymphoma (Bcl-2) protein family, has been 
identified as a survival factor in CCA.78-80 Given the pivotal role of Mcl-1 in mediating CCA 
resistance to TRAIL-induced apoptosis, 78-80 PLK inhibition is another potential strategy for the 
targeted treatment of this devastating disease. 
 
.
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3 OBJECTIVES 
The aims of the present studies were: 
1. Optimization of a modified HTK-based preservation solution focusing on chloride-
dependent effects on liver preservation injury and microcirculation after LTx. 
2. Investigation of the impact of adjuvant administered EPO on liver regeneration/donor 
liver growth and hepatocyte apoptosis in the setting of pLTx. 
3. Examination of the role of MFB-to-CCA cell paracrine signaling for CCA apoptosis 
resistance in the context of PDGF-BB/Hh co-activation networks  
4. Exploration of anti-apoptotic effects mediated by Hh/PLK signaling crosstalk. 
5. Based on the observations of 3) and 4), the objectives of subsequent studies were to test 
whether targeting PDGFR-β, Hh, or PLK signaling would be therapeutic in CCA and, 
thus, might be a suitable adjuvant therapy to optimize the Mayo LTx protocol for CCA 
patients. 
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4 METHODS 
4.1 Materials 
The chloride-poor (0.04 mmol/l) and chloride-containing (34.04 mmol/l, which is the highest 
possible chloride concentration within the confines given by all other compounds) preservation 
solutions were provided by Dr. Franz Köhler Chemie GmbH (Bensheim, Germany). EPO 
(EPREX®) was purchased from Ortho Biotech, Neuss, Germany.  
rhTRAIL, rhPDGF-BB, rhSHH, anti-human PDGF-BB antiserum AB-220-NA (R&D Systems, 
Minneapolis, MN), PKA inhibitor H-89 (Cayman Chemical, Ann Arbor, MI), MG-132 (Merck, 
Rockland, MA), GDC-0449 (Selleck, Houston, TX), and cyclopamine (LC Laboratories, 
Woburn, MA) were prepared according to the suppliers protocols. Imatinib mesylate/STI-571, 
an inhibitor of the kinase activity of PDGFR(-β), was a generous gift from E. B. Leof (Div. of 
Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN). Imatinib was dissolved 
in sterile water (10 mmol/l stock solution) and subsequently diluted in cell culture medium. 
BI 6727/volasertib, a potent selective PLK inhibitor 81 was purchased from Active Biochem 
(Maplewood, NJ), dissolved in dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO; 1 mmol/L 
stock solution) and subsequently diluted in cell culture medium for use in in vitro experiments. 
The SHH-neutralizing antibody 5E1 was obtained from the Developmental Studies Hybridoma 
Bank (DSHB, University of Iowa, IA). The construct encoding for S peptide-tagged human 
Mcl-1 mutant resistant to proteasomal degradation due to sequential mutagenesis of the 
established Mcl-1 ubiquitination sites (amino acids 5, 40, 136, 194, and 197) from lysine to 
arginine was generated as previously described. 82 
 
4.2 Cell lines/Culture/Co-Culture And Human Samples  
The human CCA cell lines KMCH-1, KMBC, HuCCT-1, TFK-1, and Mz-ChA-1 and as well 
as the erythroblastic leukemia viral oncogene homolog (ErbB-2)/neu transformed malignant rat 
cholangiocyte cell line BDEneu (CCA in vivo experiments) and the LX-2 cells, an immortalized 
myofibroblast cell line derived from human HSCs, were cultured as previously described.46, 83-
86 The human primary myofibroblastic HSCs were kindly provided by V.H. Shah (Division of 
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN) and cultured in Dulbecco's 
modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, penicillin G 
(100 U/mL), and streptomycin (100 μg/mL) under standard conditions.  
DOI:10.14753/SE.2016.1969
  13  
CCA co-culture cell experiments were performed using a transwell insert co-culture system (24 
wells) equipped with 0.4 µm pore size polyester (PET) inserts (Corning Coster, Acton, MA) 
for 6 days according to the manufacturer’s recommendations. Briefly, KMCH-1 or KMBC cells 
were plated alone or together with myofibroblastic human primary HSCs or LX-2 cells in the 
transwell insert co-culture system (KMCH-1 or KMBC cells in the bottom and human primary 
HSCs or LX-2 cells in the top wells; 1:1 ratio). First, all cells were plated alone at a density of 
2 x 103 cells/well overnight. The co-culture insert chambers with the human primary HSCs or 
LX-2 cells then were transferred the next day. Cells were treated as indicated whereas rhTRAIL 
was added at the end of the experiment (day 6) for 6 hrs and the anti-human PDGF-BB 
antiserum was added on day 5 for 24 hrs (anti-human PDGF-BB antiserum was added not 
longer than 24 hrs to minimize confounding effects on apoptosis measurement due to decreased 
cell proliferation). After rhTRAIL treatment, the KMCH-1 or KMBC cells in the bottom wells 
were analyzed for apoptosis by DAPI-staining and TUNEL assay as described in the 
“Quantitation of apoptosis” section (for the TUNEL assay, cells were plated on sterilized 
trimmed coverslips that were placed in the bottom wells prior to cell seeding). 
Human samples (from patients with intrahepatic and extrahepatic CCA treated at Mayo Clinic, 
Rochester, MN, USA) for analysis by immunohistochemistry were collected with Institutional 
Review Board approval according to the principles embodied in the declaration of Helsinki. 
 
4.3 In Vivo Microscopy 
For assessment of microvascular liver perfusion and leukocyte-endothelial interaction 
(preservation solution study) in vivo microscopy was performed 30 min after reperfusion using 
a Leica DMLM epifluorescence microscope (Leica Microsystems Wetzlar GmbH, Wetzlar, 
Germany). The left lateral liver lobe was exteriorized on a specially designed stage. The 
abdominal cavity was kept moist and body temperature was maintained constant using a heated 
operation table. Sodium fluorescein (2.0 mmol/kg; Sigma, Deisenhofen, Germany) and 
rhodamin 6G (0.1 mmol/kg; Sigma) were injected intravenously for fluorescent staining of 
hepatocytes and leukocytes, respectively.87 During the measurement, hemodynamic parameters 
(arterial blood pressure and heart rate) were monitored continuously via a polyethylene catheter 
placed in the right common iliac artery (Pressure measurement set IT2, Smiths Medical Int., 
Lancashire, UK; Dräger Infinity Delta XL monitor, Dräger Medical GmbH, Lübeck, Germany). 
Microcirculation was only assessed if the mean arterial pressure (MAP) was above 60 mmHg 
(in one case [chloride-poor preservation solution] the measurement was aborted after 40 min 
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due to systemic hypotension [technical reasons]). The following parameters were determined 
in 10 randomly selected acinar areas and postsinusoidal venules: i) diameters of sinusoids and 
postsinusoidal venules [µm]. ii) sinusoidal perfusion rate: ratio of perfused sinusoids to all 
sinusoids visible in a defined acinar area [%]. iii) red blood cell (RBC) velocity in sinusoids and 
postsinusoidal venules [µm/s]. iv) temporary leukocyte adherence in postsinusoidal venules 
(rollers): leukocytes moving along the wall of postsinusoidal venules with a velocity of less 
than 30 % of the central stream velocity (percentage of rollers of all free-moving leukocytes 
during the observation period of 20 sec [%]). v) permanent leukocyte adherence (sticker) in 
sinusoids and postsinusoidal venules: number of leukocytes adhering for at least 20 sec in 
sinusoids [n/lobule]; number of leukocytes attached for at least 20 sec to the venular surface of 
postsinusoidal venules ([n/mm2]; calculation of the visible part of the vessel surface 
[approximately 50 %, since only the back wall or the front wall of the postsinusoidal venules 
could be observed]: 0.5 · π · d · l [d = mean vessel diameter, l = vessel length]). Video tapes 
were analyzed by an examiner blinded to the experimental groups using the CapImage 7.3 
analysis software (Image Analysis System, Dr. Zeintl, Heidelberg, Germany). 
 
4.4 Light Microscopy 
4.4.1 Histological evaluation after rat liver transplantation 
Following in vivo microscopy (preservation solution study), specimens of the transplanted 
livers were taken. Histological evaluation was performed after formalin fixation, paraffin 
embedding, and hematoxylin/eosin as well as ASDCL (naphthol-AS-D-chloroacetate esterase; 
assessment of granulocyte invasion) staining by a pathologist, who also was blinded to the 
experimental groups. The severity of morphological/pathological changes was graded 
according to a numeric semiquantitative score (grade 1 = severe changes, grade 2 = moderate 
changes and grade 3 = minimal changes) evaluating the width of intrahepatic vessels, 
vacuolization in the cytoplasm of hepatocytes, prominence of Kupffer cells, necrosis/apoptosis 
as well as cholestasis. 
 
4.4.2 Morphometric analysis of vessel area/perimeter 
To assess dilatation of intrahepatic vessels (EPO study), hematoxylin-eosin stained slides were 
investigated by computed morphometry. Using an image analysis program (Zeiss KS 300, 
Oberkochen, Germany) the vessel area and perimeter was measured in central veins of the 
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hepatic parenchyma (10 randomly chosen visual fields). Results are given in µm² (area) and µm 
(perimeter), respectively. 
 
4.4.3 Immunohistochemistry for Ki-67  
Immunostaining for Ki-67, a marker for cell proliferation, was performed to evaluate the 
proliferation of hepatocytes (EPO study). The primary antibody was a rabbit monoclonal anti-
rat/mouse/human Ki-67 antigen (DCS Diagnostics, Hamburg, Germany 1:1200 dilution). 
Immunohistochemistry was performed using a biotin-free enhanced polymer one-step staining 
technique (EPOS-method) with a peroxidase-conjugated polymer backbone coupled with a goat 
anti-rabbit secondary antibody (DAKO, Hamburg, Germany). “Proliferation index” was 
defined as the percentage of Ki-67 positive cells counted in 5 high-power-fields (x40) of a 
specimen.29 
 
4.4.4 Immunohistochemistry for α-SMA, PDGFR-β, and PDGF-BB 
Immunohistochemistry for CCA studies was performed using formalin-fixed, paraffin-
embedded human and rat CCA samples (slides were also stained conventionally with 
hematoxylin/eosin). Slides were deparaffinized in xylene and rehydrated through sequential 
graded ethanol steps. For α-SMA-, PDGFR-β- and PDGF-BB-staining, the antigen retrieval 
was performed by permeabilizing the slides in 0.1% Triton X 100 for 2 min (α-SMA-staining) 
and incubation in sodium citrate (α-SMA- and PDGFR-β-staining; 0.01 M sodium citrate, 
0.05% Tween 20; pH 6.0) or Tris-EDTA buffer (PDGF-BB-staining; 0.01M Tris base, 1 mM 
EDTA solution, 0.05% Tween 20, pH 9.0) using a vegetable steamer (30 min for α-SMA- and 
60 min for PDGFR-β-/PDGF-BB-staining). After cooling, further steps were carried out 
according to the protocols of the EnVision+ System-HRP [DAB] detection kits (α-SMA: K4006 
[anti-mouse]; PDGFR-β and PDGF-BB: K4010 [anti-rabbit]; Dako, Carpinteria, CA). The 
primary antiserum against α-SMA 1A4 (MS-113-R7, ready-to-use dilution; NeoMarkers, 
Fremont, CA) was applied for 60 min at RT (PDGFR-β: P-20, 1:25, applied overnight at 4°C, 
Santa Cruz, Santa Cruz, CA; PDGF-BB: ab21234, 1:10, applied overnight at 4°C, Abcam, 
Cambridge, MA). Finally, the slides were counterstained with Mayer’s Hematoxylin Solution 
(Sigma, St. Louis, MO), mounted and examined by light microscopy.  
 
4.4.5 Immunohistochemistry for PLK1, PLK2, and PLK3 
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Immunohistochemistry (CCA studies) was performed using formalin-fixed, paraffin-embedded 
human CCA samples. Slides were deparaffinized in xylene and rehydrated through sequential 
graded ethanol steps. The antigen retrieval was performed by permeabilizing the slides in 0.1% 
Triton X 100 for 2 min and incubation in sodium citrate (0.01 M sodium citrate, 0.05% Tween 
20; pH 6.0) for 30 min using a vegetable steamer. After cooling, further steps were carried out 
according to the protocols of the EnVision+ System-HRP [DAB] detection kits (K4010 [anti-
rabbit for PLK2 and PLK3], K4007 [anti-mouse for PLK1]; Dako, Carpinteria, CA). The 
primary antiserum against PLK1 (1:200; Merck Millipore, Darmstadt, Germany; CN: 05-844), 
PLK2 (1:100; Abcam, Cambridge, MA; ab34811) and PLK3 (1:200; Proteintech, Manchester, 
UK; CN: 10977-1-AP) was applied overnight at 4°C. The slides were counterstained with 
Mayer’s Hematoxylin Solution (Sigma, St. Louis, MO), mounted and examined by light 
microscopy. PLK1/2/3 protein expression quantitation of intrahapatic and extrahepatic CCA 
samples was performed by histological grading according to the number of PLK1/2/3-positive 
cells and the intensity of PLK1/2/3 immunoreactivity (grade 0 = no protein expression, grade 4 
= high protein expression). 
 
4.5 Immunofluorescence Microscopy 
4.5.1 Staining for cytokeratin 7/TUNEL assay 
For cytokeratin 7 (CK7)-labeling (CCA studies), the antigen retrieval was performed incubating 
the slides in deionized water containing 5% urea using a vegetable steamer for 20 min (since 
some slides also were labeled for TUNEL-positive cells, an additional antigen retrieval step 
was performed with sodium citrate followed directly by cooling and application of the TUNEL 
reaction mix; the TUNEL assay is described in the “Quantitation of apoptosis” section). The 
primary antibody against CK7 (1:10; Abcam; ab9021) was applied for 30 min at RT. After 
being washed, the slides were incubated with Texas Red®-X goat anti-mouse IgG (1:1000; 
Invitrogen, Camarillo, CA; T6390) for 1 hr in the dark. The slides were then washed three times 
in PBS, one time in water and mounted using Prolong Antifade (also Invitrogen). The slides 
were analyzed by fluorescent confocal microscopy (LSM 510; Zeiss, Jena, Germany). 
 
4.5.2 Staining for PLK2 and Mcl-1 
Immunohistochemistry was performed using formalin-fixed, paraffin-embedded (cyclopamine 
CCA study) or frozen (BI 627 CCA study) rat CCA samples. Paraffin slides were deparaffinized 
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in xylene and rehydrated through sequential graded ethanol steps Antigen retrieval for the 
paraffin slides was performed by permeabilizing the slides in 0.1% Triton X 100 for 2 min and 
incubation in deionized water containing 5% urea using a vegetable steamer for 20 min with 
subsequent cooling for 20 min. Frozen slides were fixed with 4 % paraformaldehyde in PBS 
for 10 min at RT and tissue permeabilization was performed with 0.1% Triton X 100 for 15 
min at RT. After a blocking step with 5% BSA in PBS for 1 hr at RT the primary 
antisera/antibodies against PLK2 (1:50; Abcam, Cambridge, MA; ab34811) and Mcl-1 (1:100; 
Santa Cruz, Santa Cruz, CA; sc-819) were applied overnight at 4 °C. After washing, the slides 
were incubated with Alexa Fluor® 488 chicken anti-rabbit IgG (for PLK2 and Mcl-1; 1:1000; 
Invitrogen, Camarillo, CA; A21441) for 1 hr in the dark at RT. The slides were then washed 
three times in PBS, one time in water and mounted using Prolong Antifade with DAPI 
(Invitrogen). The slides were analyzed by fluorescent confocal microscopy (LSM 510; Zeiss, 
Jena, Germany) and PLK2 as well as Mcl-1 immunoreactivity was quantitated using the software 
ImageJ 1.44o (Wayne Rasband, NIH, Bethesda, MD). 
 
4.6 Microscopy For Smoothened (SMO) Trafficking 
HuCCT-1 CCA cells were cultured on coverslips, treated as indicated, and fixed with PBS 
containing 4% paraformaldehyde for 20 min at 37°C. After being washed with PBS, cells were 
incubated with 0.5% Triton X-100 in PBS for 15 min at RT and then blocked with PBS 
containing 5% BSA for 60 min at 37°C. Cells were subsequently incubated with anti-SMO 
antiserum (1:250; Santa Cruz, Santa Cruz, CA; H-300) at 4°C overnight. After being washed, 
coverslips were incubated with Texas Red®-X goat anti-rabbit IgG (1:1000; Invitrogen, 
Camarillo, CA; T6391) for 1 hr in the dark. Cells were then washed three times in PBS, one 
time in water and mounted using Prolong Antifade (Invitrogen). The slides were analyzed by 
fluorescent confocal microscopy (LSM 510; Zeiss, Jena, Germany). In additional experiments, 
SMO trafficking was examined by total internal reflection microscopy (TIRF).88 KMCH-1 cells 
cultured on coverslips were transfected with GFP-SMO plasmid 48 hours prior to study. Cells 
were treated as indicated, and fixed with ddH2O containing 2.5% formaldehyde, 0.1 M PIPES, 
1.0mM EGTA, and 3.0 mM MgSO4 for 20 min at 37°C. Cells were then washed three times in 
PBS, one time in water and mounted using Prolong Antifade (Invitrogen). The slides were 
analyzed with a TIRF microscop (Zeiss AxioObserver.Z1, Munich, Germany). GFP-SMO 
localized to the plasma membrane was quantified using image analysis software (Carl Zeiss 
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AxioVision 4.8.2.0, Munich, Germany). Data were expressed as the average fluorescence 
intensity in the cell multiplied by the number of pixels above the background. 
 
4.7 Quantitation Of Apoptosis  
Apoptosis in CCA cells was quantified by assessing the characteristic nuclear changes of 
apoptosis after staining with 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma, St. 
Louis, MO) using fluorescence microscopy.89 Terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) assays (cell co-culture and rat liver samples in the EPO and 
CCA studies) were carried out using the In situ Cell Death Detection kit (Roche, Indianapolis, 
IN) according to the supplier's protocol and as previously described.84 Caspase 3/7-activity in 
the CCA studies was quantitated using the ApoONE Homogenous Caspase-3/7 Assay 
(Promega, Madison, WI) according to manufacturer’s recommendations.89 
 
4.8 Real-Time Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted from cells and liver tissue (EPO and CCA studies) using the RNeasy 
Plus Mini Kit (Qiagen, Hilden, Germany), and was reverse-transcribed with Moloney leukemia 
virus reverse transcriptase and random primers (Invitrogen, Camarillo, CA). Quantitation of the 
complementary DNA template was performed with real-time polymerase chain reaction (PCR; 
LightCycler, Roche, Indianapolis, IN) using SYBR green (Roche) as a fluorophore.78 
Oligonucleotide sequences and expected product sizes for primer pairs used for quantitative 
RT-PCR analysis are shown in Table 2. Primer pairs for c-jun, Bcl-XL, and the EPO-receptor 
(EPO study) were purchased from Invitrogen, Mississauga, Ontario, Canada. As an internal 
control, primers for 18S rRNA (Ambion, Austin, TX) were employed. Using gel purified 
amplicons, a standard curve was generated to calculate the copy number/µL. The target mRNA 
expression level of each sample was calculated as the copy ratio of target mRNA to 18S rRNA 
and then normalized to the target mRNA expression of controls. 
 
Gene Primer sequence Product length 
 
SHH 
 
forward 5’-GATGTCTGCTGCTAGTCCTCG-3’ 
reverse 5’-CACCTCTGAGTCATCAGCCTG-3’ 
 
300 bp 
IHH forward 5’-TGGCATGCATTGGTACTCTC-3’ 
reverse 5’-GCTTGCAGCTCTATGACTAC-3’ 
350 bp 
DHH forward 5’-GAGACTCTTTCACAGCTTGG-3’ 250 bp 
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reverse 5’-TATCACCTCCTCTCAGTACG-3’ 
PTCH1 forward 5’-CCACCAGACGCTGTTTAGTCA-3’ 
reverse 5’-CGATGGAGTCCTTGCCTACAA-3’ 
72 bp 
SMO forward 5’-GTTCTCCATCAAGAGCAACCAC-3’ 
reverse 5’-CGATTCTTGATCTCACAGTCAGG-3’ 
250 bp 
Gli1 forward 5’-TGCAGTAAAGCCTTCAGCAATG-3’ 
reverse 5’-TTTTCGCAGCGAGCTAGGAT-3’ 
132 bp 
Gli2 forward 5’-TGGCCGCTTCAGATGACAGATGTTG-3’ 
reverse 5’-CGTTAGCCGAATGTCAGCCGTGAAG-3’ 
200 bp 
Gli3 forward 5’-AAACCCCAATCATGGACTCAAC-3’ 
reverse 5’-TACGTGCTCCATCCATTTGGT-3’ 
98 bp 
PDGFR-β forward 5’-AATGTCTCCAGCACCTTCGT-3’ 
reverse 5’-AGCGGATGTGGTAAGGCATA-3’ 
688 bp 
PLK1 forward 5’-CACAGTGTCAATGCCTCCAA-3’ 
reverse 5’-TTGCTGACCCAGAAGATGG-3’ 
95 bp 
PLK2 forward 5’-TCAGCAACCCAGCAAACACAGG-3’ 
reverse 5’-TTTCCAGACATCCCCGAAGAACC-3’ 
230 bp 
PLK3 forward 5’-GAAGGTGGGGGATTTTGG-3’ 
reverse 5’-GGGTGCCACAGATGGTCT-3’ 
74 bp 
Mcl-1 forward 5’-AAGCCAATGGGCAGGTCT-3’ 
reverse 5’-TGTCCAGTTTCCGAAGCAT-3’ 
121 bp 
Shh* forward 5’-CTGGCCAGATGTTTTCTGGT-3’ 
reverse 5’-TAAAGGGGTCAGCTTTTTGG-3’ 
117 bp 
Ihh* forward 5’-ACCCCACCTTCAGCGATGT-3’ 
reverse 5’-GAGTCTCGATGACCTGGAAAGC-3’ 
78 bp 
Dhh* forward 5’-CGTTACGTGCGCAAGCAA-3’ 
reverse 5’-GGTCCGCTCGGGCATACT-3’ 
69 bp 
Ptch1* forward 5’-GCAGAGGACTTACGTGGAGG-3’ 
reverse 5’-CTGACAGTGCAACCAACAGG-3’ 
245 bp 
Smo* forward 5’-GGGAGGCTACTTCCTCATCC-3’ 
reverse 5’-TAGCACATAGTCCCGGAAGC-3’ 
226 bp 
Gli1* forward 5’-TGGAAGGGGACATGTCTAGC-3’ 
reverse 5’-GCTCACTGTTGATGTGGTGC-3’ 
195 bp 
Gli2* forward 5’-CCATCCATAAGCGGAGCAAG-3’ 
reverse 5’-CCAGATCTTCCTTGAGATCAG-3’ 
105 bp 
Gli3* forward 5’-CATAGCTTCGACCTTCAGACC-3’ 211 bp 
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reverse 5’-AACCTAAGCTCTGCTGTCGG-3’ 
PDGF-B* forward 5’-TTGTGAGAAAGAAGCCAGTC-3’ 
reverse 5’-TGTGCTTAAACTTTCGGTGC-3’ 
213 bp 
PDGFR-β* forward 5’-CGAGCACCTTTGTTCTGACA-3’ 
reverse 5’-TTCTTCTCATGCAGCGTCAC-3’ 
352 bp 
PLK1* forward 5’-TTGAGGACAGCGACTTTGTG-3’ 
reverse 5’-GCGCCTTCCTCCTTTTGT-3’ 
84 bp 
PLK2* forward 5’-CACCACCATCATCACCATTC-3’ 
reverse 5’-TCGTAACACTTTGCAAATCCA-3’ 
125 bp 
PLK3* forward 5’-CTGGCAGCTCGGCTAGAG-3’ 
reverse 5’-GGCCACATAGTTGGGAGTACC-3’ 
69 bp 
Mcl-1* forward 5’-CTACTGGAGCGCGTGAGC-3’ 
reverse 5’-GGTACAGCTCGTCGTCTTCC-3’ 
100 bp 
 
Table 2.   Primer sequences and expected product sizes of human and rat primer pairs used for quantitative 
RT-PCR analysis. All primers were designed to have an optimum annealing temperature between 50 and 60 °C. 
* = rat primer pairs (all others are complementary to human targets). 
 
4.9 Immunoblot Analysis 
For CCA studies, whole cell lysates were obtained as previously described.90 For the 
examination of GLI2 activation, nuclear protein extracts were obtained using the NE-PER 
Nuclear and Cytoplasmatic Extraction Kit (Thermo Scientific , Barrington , IL; Product no.: 
78833). Primary antisera/antibodies used were: Actin (1:2000; Santa Cruz, Santa Cruz, CA; C-
11), Lamin B (1:1000; Santa Cruz, Santa Cruz, CA; M-20), PDGFR-β (1:1000; Santa Cruz, 
Santa Cruz, CA; P-20), phospho-PDGFR-β (Tyr857; 1:1000; Cell Signaling, Danvers, MA; 
#3170), GLI2 (R&D Systems, Minneapolis, MN; Antibody Part 965887 from the GLI2 
ExactaChIP Kit Catalog no.: ECP3526), PLK1 (1μg/ml; Merck Millipore, Darmstadt, 
Germany; CN: 05-844), PLK2 (1 μg/ml; Abcam, Cambridge, MA; ab34811), PLK3 (1:1000; 
Cell Signaling Danvers, MA; CN: D14F12), Mcl-1 (1:1000; Santa Cruz, Santa Cruz, CA; sc-
819), and Bcl-2 (1:1000; Santa Cruz, Santa Cruz, CA; sc-492). The mouse anti-S peptide 
antibody was a generous gift from S. H. Kaufmann (Oncology Research, Mayo Clinic, 
Rochester, MN). Horseradish peroxidase-conjugated secondary antibodies for rabbit (Santa 
Cruz; sc-2004), goat (Santa Cruz; sc-2020), mouse (Santa Cruz; sc-2031), and sheep (Santa 
Cruz; sc-2770) were incubated at a dilution of 1:2000 for 1 hr at RT. Proteins were visualized 
using enhanced chemiluminescence reagents (ECL, Amersham Biosciences, Buckinghamshire, 
UK) and Kodak X-OMAT films. 
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4.10 Chromatin Immunoprecipitation (ChIP Assay) 
ChIP was performed from KMCH-1 CCA cells treated with rhSHH (500 ng/ml, 5 hrs) 
plusminus cyclopamine (10 µM, 5 hrs) using total cellular DNA sheared to ≈ 500 bp fragments 
employing an automated cooled sonication device (Bioruptor XL; Diagenode, Denville, NJ; 20 
cycles with 30 seconds sonication/30 second intervals). ExactaCHIP chromatin 
immunoprecipitation kits for GL1, GLI2 and GL3 (R&D Systems, Minneapolis, MN; GLI1: 
ECP3324, GLI2: ECP3526, GLI3: ECP3690) and streptavidin agarose beads (Merck, 
Rockland, MA; #69203), were used following the manufacturer’s instructions. Samples were 
pre-cleared using agarose beads plus salmon sperm slurry (Upstate, Lake Placid, NY) prior to 
immunoprecipitation (also performed with agarose beads). Primers for RT-PCR were forward 
5’-TCA TGT CTC CCC GTT CCA ACT-3’, reverse 5’-TGC AAA GCC ACC CTG AAA 
GGA-3’ (PLK pomotor site I, 277 bp) and forward 5’-CAT TTG GGT CAG CTC CAA GT-3’, 
reverse 5’-TCT CAC GCC AGT TAA AAT GGC G-3’ (PLK pomotor site II, 297bp). Positive 
control primers supplied by the manufacturer were for the Bcl-2 promoter (bound by GLI1 and 
GLI2, 147 bp) and the GLI1 promoter (bound by GLI3, 211 bp). 
 
4.11 Assessment Of Laboratory Parameters 
Subsequent to in vivo microscopy (approximately 90 min after reperfusion; preservation 
solution study) blood samples were drawn (vena cava puncture) for analysis of liver enzymes 
(aspartate transaminase [AST], alanine transaminase [ALT], lactate dehydrogenase [LDH] and 
alkaline phosphatase [AP]) and prothrombin time. The samples were processed using standard 
blood analysis tests. In addition, blood samples from n=8 untreated Lewis rats were drawn as 
reference. In the EPO experiments, glutamate dehydrogenase (GLDH), total bilirubin, 
prothrombin time (PTT), international normalized ratio (INR), and hematocrit were 
additionally assessed as described before.29 Furthermore, EPO serum concentrations were 
measured by means of an immunoluminometric assay (Limbach, Heidelberg, Germany)  
 
4.12 Enzyme-Linked Immunosorbent Assay (ELISA) for PDGF-BB 
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Levels of secreted human PDGF-BB in CCA and MFB cell experiments were determined by 
an enzyme-linked immunosorbent assay using a commercially available kit (RayBiotech, 
Norcross, GA) according to the suppliers protocol.  
 
4.13 Assessment Of Bile Production 
As an indicator of liver function, postoperative bile production was measured (preservation 
solution study). The amount of bile draining from the bile duct via a polyethylene tube (prepared 
from a 22G IV Catheter, Medex Medical GmbH, Germany) over a period of 90 min was 
collected, weighed and given in mg per g of liver wet weight.  
 
4.14 cDNA Array 
A customized cDNA array consisting of 183 rat genes was established as previously described 
(EPO study).28 As a control, 13 GAPDH and ß-actin gene probes were added. Subsequently, 
the gene products were spotted on Hybond N+ nylon membranes (Amersham Pharmacia, 
Freiburg, Germany) and hybridized overnight at 65°C with P32 labeled cDNA prepared from 
10μg total RNA of each rat liver sample. The membranes were stored in a Phosphoimager 
Cassette (Amersham Biosciences, Freiburg, Germany), exposed for 2-3 days and scanned on 
the STORM Phosphoimager (Amersham Biosciences, Freiburg, Germany). The data were 
analyzed using Image Quant software (Amersham Biosciences, Freiburg, Germany) as 
described bevore.91 
 
4.15 Genome-Wide mRNA Expression Analysis 
For the CCA studies, KMCH-1 cells were treated with vehicle, PDGF-BB (200 ng/ml, 8hrs), 
or SHH (500 ng/ml, 8hrs) in the presence or absence of cyclopamine (10 μM, 8hrs). After total 
mRNA extraction (see section real time polymerase chain reaction) and confirmation of the 
sample quality by Agilent bioanalysis, 150-500 ng of total RNA per sample were analyzed for 
33617 target genes (after MAS5 noise filtering) employing an Affymetrix GeneChip Platform 
with the Affymetrix Human U133 Plus 2.0 labeling method. Specifically, biotin-labeled cRNA, 
produced by in vitro transcription, was hybridized to the Affymetrix Human Genome U133 
Plus 2.0 GeneChips. These experiments were conducted in collaboration with the Advanced 
Genomics Technology Center Core Mayo Clinic, Rochester, MN.  
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4.16 Generation Of A Transfectant Expressing SMO Short Hairpin RNA  
Short hairpin RNA (shRNA) lentiviral plasmid for SMO was from Thermo Fisher Scientific 
(Hunsville, AL; Oligo ID: V2LHS_56569; GenBank accession no.: NM_005631). KMCH-1 
CCA cells were transfected using OptiMEM I (Gibco-Invitrogen, Carlsbad, CA) containing 6 
μL/mL Lipofectamine (Invitrogen),1 μg/mL plasmid DNA, and 6 μL/mL Plus reagent 
(Invitrogen). Forty-eight hours after transfection, fresh DMEM containing 0.5 μg/mL 
puromycin was added. Surviving clones were separated using cloning rings and individually 
cultured. A clone with a scrambled shRNA was employed as a control (stable scrambled 
KMCH-1 cells). The expression/knockdown of SMO in the clones was assessed by immunoblot 
analysis.  
 
4.17 Generation Of A Transfectant Expressing PLK1, 2, or 3 Short Hairpin RNA.  
Short hairpin RNA (shRNA) lentiviral plasmids for PLK1 and PLK3 were obtained from 
Thermo Fisher Scientific/Open Biosystems (Hunsville, AL; Oligo ID: V2LHS_241437, Gen 
Bank accession no.: NM_005030 and Oligo ID: V2LHS_172853, Gen Bank accession no.: 
NM_004073, resp.). PLK2 shRNA lentiviral plasmids were obtained from Sigma-Aldrich (St. 
Louis, MO; Gen Bank accession no.: NM_006622.2). KMCH-1 cells were transfected using 
OptiMEM I (Gibco-Invitrogen, Carlsbad, CA) containing 6 µl/ml Lipofectamine (Invitrogen), 
1 µg/ml plasmid DNA and 6 µl/ml Plus reagent (Invitrogen). Forty-eight hours after 
transfection, fresh DMEM containing 0.5 µg/ml puromycin was added. Surviving clones were 
separated using cloning rings and individually cultured. A clone with a scrambled shRNA was 
employed as a control (stable scrambled KMCH-1 cells). The expression/knockdown of PLK1, 
PLK2 or PLK3 in the clones was assessed by immunoblot analysis. 
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4.18 Generation Of AN Enhanced Green Fuorescent Protein (GFP)–Tagged SMO  
A pRK7 plasmid containing the human SMO sequence (GenBank accession no.: NM_005631) 
for the CCA studies was a generous gift from M. Fernandez-Zapico (Division of Oncology 
Research, Mayo Clinic, Rochester, MN). The pRK7-SMO plasmid was modified to accept the 
green fluorescent protein (GFP) tag first by inserting recognition sites for EcoRI and NotI at 
the C-terminus of SMO, replacing the stop codon. For this, a PCR-generated EcoRI/NotI 
modified SMO C-terminal coding sequence was inserted into pRK7-SMO. Next, GFP from the 
pEGFP-N1 protein fusion vector (Clontech Laboratories, Inc., Mountain View, CA; Catalog 
no.: 6085-1; GenBank accession no.: U55762) was digested and inserted into the modified 
pRK7-SMO plasmid to generate a SMO construct fused to GFP at the C-terminal cytoplasmic 
domain. The GFP-SMO plasmid was sequenced to confirm that the construct was in frame and 
no polymerase chain reaction artifacts were introduced.  
 
4.19 GLI Reporter Construct And Promoter-Reporter Assay 
To determine GLI activity in the CCA studies, a reporter containing eight directly repeated 
copies of a consensus GLI-binding site (8x-GLI) downstream of the luciferase gene was 
employed (pδ51LucII plasmid; δ-crystalline promoter). 92 The 8x-GLI reporter was kindly 
provided by M. Fernandez-Zapico (Division of Oncology Research, Mayo Clinic, Rochester, 
MN). The plasmid was transfected into normal, stable scrambled, or shSMO KMCH-1 cells 
(0.5 μg/well) using FuGene HD (Roche Diagnosis, Basel, Switzerland). Cells were 
co-transfected with 50 ng of a plasmid expressing Renilla luciferase (pRL-CMV; Promega, 
Madison, WI). 24 hours after transfection, cells were treated as indicated, cell lysates prepared, 
and both firefly and Renilla luciferase activities quantified using the Dual-Luciferase Reporter 
Assay System (Promega) according to the manufacturer’s instructions. Firefly luciferase 
activity was normalized to Renilla luciferase activity to control for transfection efficiency and 
cell numbers. Data (firefly/Renilla luciferase activity) are expressed as fold increase over 
vehicle-treated cells transfected with the 8x-GLI/pRL-CMV reporter constructs. 
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4.20 Animal Experiments 
4.20.1 Orthotopic full size rat liver transplantation 
Male Lewis and Wistar rats (240–300 g) were obtained from the Central Animal Facility of the 
University Hospital Essen (preservation solution studie). Animals were kept under standard 
conditions with free access to food (recipient rats were fastened for 2 h preoperatively) and 
water. All operations and handling procedures were conducted in accordance with the German 
Animal Welfare Law and with approval of the district administrative authorities 
(Regierungspräsidium Düsseldorf and Landesamt für Natur, Umwelt und Verbraucherschutz 
Recklinghausen). Surgical procedures and interventions were performed under volatile 
anesthesia (O2 with up to 2.5 % isoflurane) with maintained spontaneous ventilation. The study 
was subdivided into two parts in order to compare the effects of the new HTK solutions (for 
composition see Table 1) on i) overall survival under different conditions and ii) 
microcirculation as well as laboratory and histological parameters.  
Three different microsurgeons performed orthotopic LTx in male Lewis and Wistar rats (donors 
and recipients: 240–300 g) according to the cuff technique described by Kamada and Calne 
without hepatic artery reconstruction.93 Perfusion (approx. 50 ml) and storage (150 ml) of the 
livers at 4°C were done using the same preservation solution (chloride-poor vs. chloride-
containing new solution). The following three protocols were carried out for comparison of 
overall survival. Protocol 1: CIT: 24 h; WIT (during implantation): 17.1 ± 1.6 min; Wistar to 
Wistar; n=7 recipient rats each group; randomized; sacrifice after 7 days. Protocol 2: CIT: 12 h; 
WIT: 19.7 ± 3.2 min; Wistar to Wistar; n=8 recipient rats each group; randomized; blinded; 
sacrifice after 7 days. Protocol 3: CIT: 3 h; WIT: 25.0 ± 0.0 min (fixed to 25.0 min; no standard 
deviation); Lewis to Lewis; n=8 recipient rats each group; randomized; blinded; sacrifice after 
28 days. LTx prior to assessment of microcirculatory parameters was performed according to 
the following protocol with average CIT and WIT: CIT: 18 h; WIT: 18.0 ± 1.1 min; n=7/8 
Lewis rats each group; randomized; blinded (one rat [chloride-containing preservation solution] 
died of unknown reasons 30 min after beginning of in vivo microscopy); sacrifice directly after 
in vivo microscopy. Analgesia in all rats was achieved by preoperative subcutaneous injections 
of 5 mg/kg BW carprofen (Rimadyl®, Pfizer, Karlsruhe, Germany). Recipient rats participating 
in survival experiments additionally obtained 100 mg/kg BW mezlocillin (Baypen®, Bayer AG, 
Leverkusen, Germany) intramuscularly after LTx as antibiotic prophylaxis. 
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4.20.2 Orthotopic partial (30%) rat liver transplantation 
Male Lewis rats (Charles River Laboratories, Sulzfeld, Germany) weighing 250-300g were 
maintained on a commercial pelleted diet and water ad libidum under normal laboratory lighting 
conditions (EPO studie). All animal study protocols were approved by the German Animal 
Welfare Law and with approval of the district administrative authorities (Regierungspräsidium 
Düsseldorf and Landesamt für Natur, Umwelt und Verbraucherschutz Recklinghausen). 
For transplantation, donor and recipient rats underwent isoflurane anesthesia. Liver reduction 
was achieved by resecting the left lateral and median lobe, which resulted in a 70% reduction 
of the liver mass. The graft was flushed and stored in cold HTK solution with a CIT of 180 
minutes (sacrifice after 24 h) and 360 min. (sacrifice after 28 days = survival experiments), 
respectively. pLTx was performed according to the cuff technique of Kamada and Calne 
without hepatic artery reconstruction.93 The transplantation procedure required less than 60 
min. The portal vein was clamped for 16 to 19 min. After the observation period (see protocols 
below), the remnant, regenerated liver was resected, weighed and total body weight was 
measured. The acquired data were expressed as percentage of the ratio between remnant liver 
weight (A), divided by the total body weight (B) times 100 (Liver body weight ratio [LBWR] 
in (%) = A/B x 100). 
Preconditioning experiments (protocol 1) were carried out to establish optimal EPO-doses for 
donor animals. Controls were treated with heat-inactivated EPO in the same vehicle volume. 
The following protocols were employed. Protocol 1: In two preconditioning experiments rats 
(n=8 in each group) were injected once or thrice with several doses of EPO i.p. The animals 
were sacrificed 4, 8 and 12 days after the first injection. Protocol 2: Donor rats (n=8 in each 
group) were injected thrice with 1 I.U. EPO/g BW i.p. or vehicle 9 days prior to partial liver 
transplantation (pLTx). Recipient rats were injected thrice with 5 I.U. EPO/g BW or vehicle 
i.v. perioperatively. The animals were sacrificed after 24 h and 28 days (survival experiments) 
postoperatively. 
 
4.20.3 Syngeneic, orthotopic rat modell of cholangiocarcinoma 
All CCA animal studies were performed in accordance with and approved by the Institutional 
Animal Care and Use Committee. In vivo intrahepatic cell implantation was carried out in male 
adult Fischer 344 rats (Harlan, Indianapolis, IN) with initial body weights between 190 and 230 
g as previously described.84-86 In the experiments targeting PDGF siganaling, imatinib mesylate 
(30 mg/kg BW; approx. 0.5 mL) or vehicle (normal saline) was given intraperitoneally every 
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day for one week (1st injection: 7th post-operative day; 7th injection: 13th post-operative day). In 
the experiments targeting Hh siganaling, cyclopamine (2.5 mg/kg BW; 0.5 mL) complexed 
with 2-hydroxypropyl-β-cyclodextrin (Tocris, Ellisville, MO) as previously described 94, 95 or 
vehicle was given intraperitoneally every day for one week (1st injection: 7th post-operative day; 
7th injection: 13th post-operative day). In the experiments targeting PLK siganaling, BI 6727 (3 
injections of 10 mg/kg body weight [0.5 mL] intraperitoneally every other day; the first 
injection was given on postoperative day 7,and the third injection was given on postoperative 
day11) formulated in hydrochloric acid (0.1 N) diluted with 0.9% NaCl.81 Twenty-four hours 
(forty-eight hours in the BI 6727 study) after receiving the last injection, the rats were 
euthanized and the livers removed for further analysis including histopathology and mRNA 
extraction. To assess the numbers of metastases-free and metastases-bearing rats, the abdominal 
cavities, the retroperitoneal spaces and the thoracic cavities were thoroughly examined as 
previously described.85 
 
4.21 Statistical Analysis 
4.21.1 Preservation solution/erythropoietin studies 
All data are expressed as mean ± SD unless indicated otherwise and represent at least three 
independent experiments. Comparison between experimental groups was performed using the 
two-tailed Student’s t-test for quantitative continuous variables. Overall survival curves were 
estimated with the Kaplan-Meier method and statistical analysis was performed using the 
logrank test for each single series and Fishers-combination rule to calculate an overall one-sided 
p-value that combines the results from all three independent survival experiments. Further 
statistical analyses (EPO study) were performed by one-way Anova or Wilcoxon´s test. 
Differences were considered as significant at levels of p < 0.05. Statistical analysis was 
performed using GraphPad Prism v4.00 (GraphPad Software Inc., La Jolla, CA) and SPSS 
v12.0 (SPSS Inc., Chicago, IL). 
 
4.21.2 Cholangiocarcinoma studies 
Data are expressed as the mean ± s.e.m. unless indicated otherwise and represent at least three 
independent experiments. Box-and-whisker plots depict minimum, 25th percentile, median, 75th 
percentile, maximum, and outliers. Differences in experiments with two groups were compared 
using the two-tailed Student t-test or the Chi-square test (2, analysis of metastasis) as well as 
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Mann Whitney’s test (analysis of PLK1/2/3 expression in human CCA samples). Differences 
in experiments with more than two groups were compared using ANOVA with Bonferroni post 
hoc correction. Differences were considered as significant at levels of p < 0.05. Statistical 
analysis was performed using GraphPad Prism v4.00 (GraphPad Software Inc., La Jolla, CA). 
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5 RESULTS 
5.1 General Optimization Approaches For Liver Transplantation 
5.1.1 Chloride improves survival due to beneficial effects on microcirculation 
Postoperative survival. Each of the three experimental series performed to assess postoperative 
survival showed a (strong) tendency towards a prolonged survival using the chloride-containing 
new solution. In the first series (n=7 Wistar rats/group) a long CIT (24 h) was combined with a 
short WIT (17.1 ± 1.6 min). Here the survival rates 7 days after LTx were 100 % vs. 71.4 % 
(2 = 2.16 [p>0.05 by logrank test]) for the chloride-containing vs. the chloride-poor solution, 
respectively (Figure 1A). The second series (n=8 Wistar rats/group) was carried out with 
intermediate CITs and WITs (12 h/19.7 ± 3.2 min). Figure 1B depicts the Kaplan-Meier 7d-
survival plot with 75 % of the rats surviving after LTx with the chloride-containing solution in 
comparison with 37.5 % of the rats still living 7 days after LTx with the chloride-poor solution 
(2 = 1.70 [p>0.05 by logrank test]). While follow-up time in the first two series utilizing Wistar 
rats was limited to 7 days in order to avoid influences due to rejection reactions (the Wistar rats 
are not inbred), Lewis rats (a syngeneic strain) in the third series (n=8 Lewis rats/group) with a 
short CIT (3 h) and long a WIT (fixed to 25.0 min; no standard deviation) were observed over 
a period of 28 days (Figure 1C). In this series with a median survival of 23.5 vs. 9.5 days, for 
the third time the survival rates between animals receiving grafts preserved with the chloride-
containing new solution vs. animals receiving grafts preserved with the chloride-poor new 
solution suggested a better outcome with chloride (50 % vs. 12.5 %, 2 = 3.06 [p=0.07 by 
logrank test]). After combining the results from the three independent experimental series using 
Fishers-combination rule, an overall one-sided p-value of 0.012 was obtained, underlining the 
results shown in Figure 1A-C by a statistical summary. 
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Figure 1.   Overall survival of different rat strains after LTx by 3 different microsurgeons with the chloride-
poor and chloride-containing solutions. (A) Kaplan-Meier 7-day survival plot (CIT = 24 hours, WIT = 17.1 ± 
1.6 minutes, 7 Wistar rats in each group, P = 0.14), (B) Kaplan-Meier 7-day survival plot (CIT = 12 hours, WIT = 
19.7 ± 3.2 minutes, 8 Wistar rats in each group, P = 0.19), and (C) Kaplan-Meier 28-day survival plot (CIT = 3 
hours, WIT = 25.0 ± 0.0 minutes, 8 Lewis rats in each group, P = 0.07). A combination of the results from all 3 
experimental series with Fisher’s method yielded an overall 1-sided P value of 0.012. 
 
Microcirculation. Assessment of microcirculation and leukocyte-endothelial interaction was 
performed in an additional series with an intermediate CIT (18 h) and an intermediate WIT 
(18.0 ± 1.1 min; Table 3). In this series systemic hemodynamic parameters, i.e. arterial blood 
pressure and heart rate were also measured since these systemic parameters have a relevant 
impact on hepatic microcirculation. There were no significant differences between the rats of 
both test groups in regard to systemic hemodynamics, body weight, and liver wet weight (Table 
3). 
 
 
Table 3.   General, physiological, and LTx data for the test groups participating in the in vivo microscopy 
experiments. The experiments were performed with 7 or 8 Lewis rats in each group. *At the beginning of the in 
vivo microscopy analysis. 
 
In vivo microscopy starting 30 min after reperfusion exhibited obvious pathological alterations 
such as intraparenchymal hemorrhages, areas with reduced RBC velocities, and stasis of blood 
flow in both test groups. These disturbances of microcirculation were observed in both 
sinusoids and postsinusoidal venules. However, number and size of malperfused areas were 
clearly decreased in rats that underwent LTx with grafts preserved with the chloride-containing 
preservation solution. This impression was confirmed by quantitative analysis (carried out in a 
blinded fashion) exhibiting clearly higher sinusoidal perfusion rates in liver grafts preserved 
with the chloride-containing new solution at start point, end point, and during 60 min (mean) 
of in vivo microscopy (Figure 2A). In addition, mean RBC velocities in sinusoids and 
postsinusoidal venules were clearly higher with the chloride-containing new solution (Figure 
2B). The most significant RBC velocity difference was observed at the end point of in vivo 
microscopy (90 min after reperfusion) in postsinusoidal venules (339.0 ± 95.9 µm/s vs. 
182.1 ± 41.1 µm/s; p = 0.001). While sinusoidal perfusion rates and RBC velocities remained 
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relatively constant in both test groups during the whole period of the measurement, diameters 
of postsinusoidal venules (not sinusoids) showed differences over time (Table 4). Interestingly, 
diameters of postsinusoidal venules in liver grafts preserved kkkk 
 
Figure 2.   Microcirculation 30 to 90 minutes after reperfusion with the chloride-poor solution (white boxes) 
and the chloridecontaining solution (gray boxes). (A) sinusoidal perfusion rates at the beginning and end of the 
in vivo microscopy analysis (30 and 90 minutes after reperfusion, respectively) and during 60 minutes of the 
analysis (mean rates from 30 to 90 minutes after reperfusion). (B) RBC velocities in sinusoids and postsinusoidal 
venules. The LTx protocol was as follows: CIT =18 hours, WIT = 18.0 ± 1.1 minutes, and there were 7 or 8 Lewis 
rats in each group. Box and whisker plots depict the distributions of the measurements (the box limits are the 25th 
and 75th percentiles, the medians are marked between them, and the whiskers depict the 
minima and maxima). *P < 0.05 and **P < 0.01. 
 
 
with the chloride-containing solution increased over the 60 min observation period, while 
preservation with the chloride-poor solution led to a decrease in postsinusoidal venule diameters 
within the same time. At the end of in vivo microscopy these reverse developments resulted in 
significantly wider postsinusoidal venule diameters within liver grafts that were preserved with 
the chloride-containing preservation solution (Table 4). 
 
Leukocyte-endothelial interaction. Although the number of stickers per surface postsinusoidal 
venule increased with time in both test groups there were no significant differences concerning 
any parameter of leukocyte-endothelial interaction comparing the chloride-containing vs. the 
chloride-poor preservation solution (Table 4). 
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Table 4.   Vessel diameters and leukocyte-endothelium interactions. The LTx protocol was as follows: CIT = 
18 hours, WIT = 18.0 ± 1.1 minutes, 7 or 8 Lewis rats in each group. Only 2 parameters (diameter of postsinusoidal 
venules and stickers in postsinusoidal venules) showed notable differences between the starting points and 
endpoints of the in vivo microscopy analysis. 
 
Liver histology. No signs of necrosis/apoptosis or cholestasis were observed in either test groups 
90 min after reperfusion. In addition, no granulocyte invasion occurred with exception of 
minimal cell counts of neutrophilic granulocytes in a few periportal tracts. Comparing the 
chloride-containing vs. the chloride-poor preservation solution, there were no significant 
differences with regard to postmortal width of intrahepatic vessels (severity score of 
morphological/pathological parameters [semiquantitative score; 1-3 = high-grade to low-
grade]: 1.4 ± 0.5 vs. 1.6 ± 0.7), vacuolization in the cytoplasm of hepatocytes (1.4 ± 0.7 vs. 2.0 
± 0.9) as well as prominence of Kupffer cells (2.0 ± 0.5 vs. 2.0 ± 0.5). 
Laboratory parameters. In both test groups postoperative serum transaminase and LDH 
activities were clearly increased 90 min after reperfusion in comparison with non-treated 
animals (reference). However, rats that underwent LTx with the chloride-containing 
preservation solution exhibited lower serum transaminase (AST, ALT) and LDH activities than 
rats after LTx with the chloride-poor preservation solution (Figure 3A). Statistical significance 
was barely missed (p = 0.087; p = 0.118; p = 0.052). AP activity was not notably increased 
compared to non-treated animals in both test groups. Prothrombin time was slightly elevated 
possibly due to consumption of clotting factors at this early time point, but also did not show 
any difference when comparing the chloride-containing vs. the chloride-poor preservation 
solution (Figure 3B).  
 
Bile production. As a parameter of hepatocellular function bile flow was significantly less 
impaired in rats that underwent LTx with the chloride-containing new solution (Figure 3C).  
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Figure 3.   Serum liver enzyme activities and prothrombin time 90 min after reperfusion as well as bile 
production during a period of 90 min after reperfusion comparing the chloride-poor () vs. the chloride-
containing () solution.  (A) Aspartate transaminase (AST), alanine transaminase (ALT) and lactate 
dehydrogenase (LDH). B: Alkaline phosphatase (AP) and prothrombin time (PT). C: Bile production given in mg 
per g of liver wet weight. Grey hatched bars = references consisting of mean values collected from blood samples 
of n=8 untreated Lewis rats. LTx protocol: CIT = 18 h; WIT = 18.0 ± 1.1 min; n=7/8 Lewis rats each group. Box-
and-whisker plots depicting the distribution of measurements (limits of the box are the minimum, 25 th and 75th 
percentile with the median marking in between; ○ = outliners). *P < 0.05. 
 
 
5.1.2 Erythropoietin increases liver growth and inhibits apoptosis 
Systemic effects of EPO. To demonstrate correct application and efficacy of EPO, we measured 
EPO serum concentrations and hematocrit in the rats after three successive intravenous 
injections of 5 I.U. EPO/g BW. There were no changes of the hematocrit within the first 48 h. 
96 h after the first of three EPO-injections, however, the hematocrit rose from 42% ± 2% to 
49% ± 3% (p=0.028; n=8). The EPO serum concentrations in treated rats (n=8) reached levels 
that were 569 times higher than in control animals (796 mU/ml ± 214 mU/ml vs. 1.4 mU/ml ± 
0.3 mU/ml; p<0.001; n=8). 
 
EPO effects on growth of unresected (donor) livers. EPO treatment resulted in a steady increase 
of cellular mass of the liver after the first EPO injection, as indicated by an elevated LBWR 
compared to control animals. The highest LBWR was achieved by applying 1 I.U. EPO/g BW 
i.p. thrice on three successive days (3.80% ± 0.12% vs. 3.56% ± 0.15%; p=0.016). Applying 
1 I.U. EPO/g BW i.p. once led to a higher LBWR compared to control animals, but was lower 
than in animals, which had received EPO three times. There was nu further increase of the 
LBWR upon doubling the amount of EPO (2 I.U. EPO/g BW i.p. thrice). In contrast, reducing 
the dosage to 0.5 I.U. led to a smaller increase of the LBWR.  
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EPO effects on hepatocyte proliferation in unresected (donor) livers. The increase of liver mass 
was accompanied by an increase in Ki-67 proliferation index. EPO-treated rats showed the most 
significant increase of hepatocyte proliferation 12 days after EPO application with 4.6% ± 1.3% 
vs. 1.1% ± 0.5% in control rats when receiving 1 I.U. EPO/g BW i.p. thrice on three successive 
days compared to controls (p<0.001).  
 
EPO effects on growth of partial liver grafts (donor and recipient). In these experiments, we 
investigated the impact of preconditioning (donor rats) and perioperative treatment with EPO 
after pLTx (recipient rats). To assess liver regeneration, LBWR was measured (Figure 4A). 
After 24 h, recipients of the EPO-group showed a higher absolute liver weight-increase in 
comparison with control rats (0.58g ± 0.23g vs. 0.37g ± 0.13g; p=0.046). The relative increase 
in liver weight was significantly higher 15.7% ± 6.74% in EPO-treated compared to control 
animals (9.9% ± 2.68%, p=0.040).  
 
 
Figure 4.   EPO effects in the setting of partial liver transplantation (pLTx). (A) Absolute and relative liver-
to-body weight ratio (LBWR) after pLTx. Animals were treated with EPO or heat-inactivated EPO in the same 
vehicle volume. LBWR increased 24 h and 5 days after pLTx regarding absolute and relative LBWR. (B) 
Hepatocyte apoptosis (TUNEL index) after pLTx. Hepatocyte apoptosis was assessed in rat livers 24 h after pLTx. 
There was a significantly lower proportion of hepatocytes undergoing apoptosis 24 h after pLTx (0.56% 
vs. 1.03%, P=0.04) compared with control rats. (C) Twenty-eight-day survival after pLTx. Sixteen rats were 
investigated for overall survival after undergoing 30% pLTx. EPO-treated animals showed an improved overall 
survival after pLTx. Only one animal died within the EPO group, whereas five rats died in the control arm 
(*P < 0.05.; χ2=Chi-square value). 
 
 
EPO effects on hepatocyte proliferation in partial liver grafts. Twent-four hours after pLTx the 
increase of liver mass in the EPO-group was accompanied by a trend towards a higher Ki-67-
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proliferation index. However, due to a high standard deviation, no statistical significance was 
obtained (12.7% ± 12.7% vs. 4.74% ± 2.2%; p=0.1). 
 
EPO effects on laboratory parameters after pLTx. Twenty-four hours after pLTx there were no 
significant differences concerning postoperative raises of AST (3852 U/l ± 2221 U/l vs. 4097 
U/l ± 1208 U/l), ALT (1981 U/l ± 655 U/l vs. 2145 U/l ± 1234 U/l), GLDH (2345 U/l ± 1343 
U/l vs. 2546 U/l ± 1622 U/l) and total bilirubin (0,9 mg/dl ± 1,23 mg/dl vs. 0,83 mg/dl ± 0,76 
mg/dl) in EPO vs. control rats. However, there was a trend towards an improved postoperative 
coagulation in the EPO group (INR: 1.27 ± 0.14 vs. 1.41 ± 0.05; p=0.06; PTT: 18.96s ± 4.83s 
vs. 23.48s ± 1.28s; p=0.08).  
 
EPO effects on hepatocyte apoptosis in partial liver grafts. For hepatocyte apoptosis analysis, 
TUNEL staining was performed in rats after pLTx. There was a significantly lower proportion 
of hepatocytes undergoing apoptosis 24 h after pLTx (0.56% vs. 1.03%; p<0.04) as compared 
to control rats (Figure 4B). 
 
EPO effects on gene expression in partial liver grafts. In order to examine the mechanistic 
processes underlying our prior observations, the expression of 183 genes involved in liver 
regeneration and apoptosis were measured by a customized cDNA array. Relevant results were 
confirmed by quantitative RT-PCR. Finally, the immediate-early gene c-jun as well as the anti-
apoptotic gene Bcl-XL were confirmed to be significantly upregulated in the EPO-group. In 
contrast, the gene expression of the EPO-receptor was not altered (Table 5).  
 
EPO effects on angiogenesis in partial liver grafts. The morphometric parameters vessel 
perimeter (346 µm² ± 50 µm² vs. 324 µm² ± 104 µm²; p>0.05) and vessel area (8653 µm² ± 
2951 tµm² vs. 7532 µm² ± 4766 µm²; p>0.05) did not reveal differences in early angiogenesis 
24 h after surgery. 
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Table 5.   Gene expression analysis by RT-PCR. Twent-four hours after pLTx, mRNA level alterations of 
relevant genes were assessed (mRNA fold changes within 24 h in EPO-treated versus control rats; n=8 each). 
 
Impact of treatment with EPO on 28-day survival after pLTx. Finally, twenty-eight-day survival 
was assessed in additional 16 rats (Figure 4C). We observed an overall survival of 88% (7/8) 
in rats receiving EPO as compared to only 38% (3/8) in control rats at the end of the observation 
period as demonstrated by the Kaplan-Meier survival curve (p=0.03; Chi-square [2] = 4.7). All 
animal deaths occurred within the first week after transplantation.  
 
5.2 Optimization Of Liver Transplantation For Cholangiocarcinoma 
5.2.1 Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling  
Expression of PDGF-BB by MFBs and PDGFR-β by CCA cells. Initially, we assessed basal 
PDGF-BB secretion by two human CCA cell lines, KMCH-1 and KMBC, primary HSC cells, 
and the human MFB cell line LX-2 by ELISA (monoculture conditiones, Figure 5A). The MFB 
cells secreted significantly higher levels of PDGF-BB than the CCA cell lines. Because many 
cancer cells do not express PDGF receptors, 96 we next examined KMCH-1 cells for the 
presence of PDGFR-β and its activating phosphorylation by PDGF-BB (Figure 5B). 
Immunoblot analysis confirmed protein expression of PDGFR-β in KMCH-1 cells (Figure 5B, 
lower), while PDGFR- was not detectable (data not shown). PDGFR-β also displayed receptor 
phosphorylation (Tyr857) upon PDGF-BB treatment (Figure 5B, upper). In addition, we 
confirmed mRNA expression of PDGFR-β in KMCH-1 cells and 4 other human CCA cell lines 
(KMBC, HuCCT-1, TFK-1, and MzChA-1) as well as in the ErbB-2/neu transformed malignant 
rat cholangiocyte cell line BDEneu (employed in the in vivo CCA model; Figure 6) 
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Figure 5.   Cellular expression of PDGF-BB, PDGFR-β, and α-SMA in CCA. (A, B) PDGF-BB is secreted by 
MFBs and phosphorylates PDGFR-β in CCA cells in vitro (A) Basal PDGF-BB secretion (24 hours; corrected for 
total protein expression) by two human CCA cell lines, KMCH-1 and KMBC, a human myofibroblast (MFB) cell 
line, LX-2, and myofibroblastic human primary HSC cells (Hu.Pr.) was assessed in the serum-free supernatant by 
ELISA (monoculture conditiones). Mean ± s.e.m. (n=3). (B) KMCH-1 cells (serum-starved for 2 days) were 
treated with vehicle or PDGF-BB at the concentrations and time intervals indicated. Cell treatment was followed 
by immunoblot analysis for PDGFR-β and phospho-PDGFR-β (Tyr857).Upper bands show the N-linked 
glycosylated and lower bands the unglycosylated forms of PDGFR-β. (C) α-SMA (MFB marker; left), PDGFR-β 
(middle), and PDGF-BB (right) protein expression (brown) was examined by immunohistochemistry 
(counterstaining with Mayers’ Hematoxylin; photomicrographs were taken in 600x magnification) in human CCA 
specimens. 
 
 
To characterize the expression of α-SMA, PDGFR-β, and PDGF-BB in vivo, we performed 
immunohistochemistry for these proteins in human CCA specimens (Figure 5C). Numerous α-
SMA-positive MFBs were present in the stromal tumor microenvironment in all human CCA 
samples examined (Figure 5C, left). Moreover, PDGFR-β immunoreactivity was confirmed in 
CCA cell glands in approximately half of the samples (Figure 5C, middle), whereas PDGF-BB 
was expressed in MFBs in two-thirds of the samples (Figure 5C, right). Thus, PDGF-BB was 
shown to be secreted by MFBs and its receptor expressed by CCA cells. 
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Figure 6.   PDGFR-β expression in 6 CCA cell lines. mRNA expression levels of PDGFR-β was assessed by 
qualitative RT-PCR analysis in the 5 human CCA cell lines KMCH-1, KMBC, HuCCT-1, TFK-1, and MzChA-1 
(left of the 100bp-DNA ladder) as well as in the ErbB-2/neu transformed malignant rat cholangiocyte cell line 
BDEneu (employed in the in vivo CCA model; right of the 100bp-DNA ladder). 
 
 
MFB-derived PDGF-BB promotes resistance to TRAIL cytotoxicity. Next, we examined the 
effect of co-culturing KMCH-1 cells with PDGF-BB-secreting myofibroblastic human primary 
HSCs (Figure 7A and C) or LX-2 cells (Figure 7B and D) on TRAIL-induced CCA cell 
apoptosis. As assessed by either nuclear morphology (Figure 7A and B) or the TUNEL assay 
(Figure 7C and D), KMCH-1 cells were more resistant to TRAIL-induced apoptosis when co-
cultured with human primary HSCs or LX-2 cells as compared to monoculture conditions. 
Interestingly, the KMCH-1 cells were resensitized to TRAIL (10 ng/mL) when co-cultured in 
the presence of neutralizing anti-human PDGF-BB antiserum (Figure 7A-D). Thus, PDGF-BB 
secreted by co-cultured MFB cells, reduces the susceptibility of CCA cells to TRAIL-induced 
apoptosis.  
 
PDGF-BB cytoprotection is dependent on Hh signaling. Given that PDGF-BB modulates anti-
apoptotic Hh signaling in immature cholangiocytes 58 and Hh signaling appears to be a potent 
survival signal for CCA cells, 67, 68 we explored the effect of Hh signaling inhibition on PDGF-
BB-mediated cytoprotection against TRAIL cytotoxicity. Apoptosis was assessed 
morphologically following DAPI-staining (Figure 8A upper and B) and biochemically 
hhhhhhhhh 
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Figure 7.   PDGF-BB promotes resistance to TRAIL cytotoxicity. KMCH-1 cells were plated alone 
(monoculture) or together with PDGF-BB-secreting human primary HSCs (Hu.Pr.; A and C) or LX-2 (B and D) 
cells in a transwell insert co-culture system (KMCH-1 cells in the bottom and human primary HSCs or LX-2 cells 
in the top wells; 1:1 ratio) for 6 days. Cells were treated as indicated with vehicle (V), rhTRAIL (T; 10ng/mL for 
6 hrs on day 6) or rhTRAIL plus anti-human PDGF-BB antiserum (T + AB-P; rhTRAIL: 10ng/mL for 6 hrs on 
day 6; anti-human PDGF-BB antiserum: 10µg/mL for 24 hrs on day 5). After rhTRAIL treatment for 6 hrs, 
KMCH-1 cells were analyzed for apoptotic nuclear morphology by DAPI-staining (A and B) and for DNA 
fragmentation by TUNEL-staining (C and D) with quantitation of apoptotic nuclei by fluorescence microscopy. 
Mean ± s.e.m. (n=5). (C and D left) Representative fluorescent photomicrographs of TUNEL-positive KMCH-1 
cells are depicted. 
 
by a caspase-3/-7 activity assay (Figure 8A lower). Exogenous PDGF-BB protected KMCH-1 
cells from TRAIL-induced apoptosis (Figure 8). In contrast, cyclopamine, an inhibitor of SMO  
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Figure 8.   Cytoprotection by PDGF-BB is dependent on Hh signaling. (A) First, KMCH-1 cells (serum-starved 
for 2 days) were treated with vehicle or PDGF-BB (200 ng/mL) for 8 hrs. PDGF-BB was retained in the culture 
media, and the cells were then treated with rhTRAIL (5 ng/mL), cyclopamine (a Hh [SMO] inhibitor; 5 µM) or 
TRAIL plus cyclopamine (5 ng/mL; 5 µM) for additional 6 hrs. (B) Similar experiments (same PDGF-BB and 
TRAIL treatment) were performed with shSMO KMCH-1 instead of cyclopamine-treated KMCH-1 cells (lower) 
and stable scrambled KMCH-1 instead of normal KMCH-1 cells (controls, upper). (C) Stable knockdown of SMO 
only in shSMO KMCH-1 cells was confirmed by immunoblot analysis. Apoptosis was measured by 
DAPI-staining with quantitation of apoptotic nuclei by fluorescence microscopy (A upper and B; mean ± s.e.m.; 
n=3) or fluorescent analysis of caspase-3/-7 activity (A lower; mean ± s.e.m.; n=6; RFU, relative fluorescence 
unit). 
 
(the transducer of Hh signaling) 97 sensitized KMCH-1 cells to TRAIL-induced apoptosis (Fig. 
Figure 8A). Moreover, cyclopamine completely abrogated PDGF-BB inhibition of 
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TRAIL-induced apoptosis (Figure 8A). Likewise, shSMO KMCH-1 cells also underwent 
TRAIL-mediated apoptosis despite exogenous PDGF-BB treatment (Figure 8B lower; compare 
with stable scrambled KMCH-1 cells Figure 8B upper). Taken together, these observations 
suggest that PDGF-BB-mediated protection from TRAIL-induced apoptosis is dependent upon 
an intact Hh signaling pathway. 
 
PDGF-BB induces translocation of SMO to the plasma membrane. We next sought to explore 
how PDGF-BB stimulates Hh signaling in order to promote CCA cell survival. Initially, we 
analyzed the direct effect of PDGF-BB on mRNA expression of the Hh signaling ligands SHH, 
IHH and DHH as well as PTCH1, SMO, and GLI1-3 by quantitative RT-PCR (Figure 9A). 
PDGF-BB did not significantly alter mRNA expression of the three Hh ligands nor that of 
PTCH1, SMO, or GLI1-3 in KMCH-1 and HuCCT-1 cells.  
 
 
 
Figure 9.   PDGF-BB has no effect on mRNA expression of members of the Hh signaling pathway. (A) The 
two human CCA cell lines (serum-starved for 2 days) KMCH-1 (upper) and HuCCT-1 (lower) were treated with 
vehicle or PDGF-BB (500 ng/mL) for 8 hrs followed by quantitative RT-PCR analysis for mRNA expression of 
the Hh signaling mediators sonic (SHH), indian (IHH), and desert hedgehog (DHH) as well as patched-1 (PTCH1), 
smoothened (SMO), and glioma-associated oncogenes (GLI) 1-3. 18S ribosomal RNA was used to normalize 
expression. Mean ± s.e.m. (n=3). 
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Because translocation of SMO from intracellular vesicles to the plasma membrane results in its 
activation during Hh signaling, 64 we next examined the cellular localization of SMO upon 
PDGF-BB treatment by immunocytochemistry (Figure 10A). PDGF-BB significantly induced 
translocation of SMO from intracellular compartments to the plasma membrane (Arrows; 
Figure 10A, middle). This process appears to be PKA-dependent as it was effectively attenuated 
by the PKA inhibitor H-89. Similar results were obtained when we employed KMCH-1 cells 
transiently transfected with a plasmid expressing GFP-tagged human SMO and analyzed GFP-
SMO localized at the plasma membrane by TIRF microscopy 68 (Figure 10B). As a further 
indicator for Hh signaling activation, we examined the effect of PDGF-BB on GLI2 nuclear 
translocation in KMCH-1 cells by immunoblot analysis (Figure 10C). PDGF-BB treatment 
increased GLI2 abundance in nuclear protein extracts, an effect that again was attenuated by 
the PKA inhibitor H-89. Consistent with these results, KMCH-1 cells transiently transfected 
with a GLI reporter construct displayed GLI activation upon PDGF-BB treatment. The SMO 
inhibitor cyclopamine effectively blocked PDGF-BB-mediated GLI activation (Figure 10D 
upper). Likewise, stable scrambled KMCH cells also displayed PDGF-BB-induced GLI 
activation, whereas no PDGF-BB effect was observed in shSMO KMCH-1 cells (Figure 10D 
lower). Thus, PDGF-BB appears to promote Hh signaling-dependent cytoprotection by 
inducing PKA-mediated SMO trafficking to the plasma membrane.  
To further characterize the PDGF-BB-stimulated, SMO-dependent gene regulation, we finally 
also identified 67 target genes to be commonly up-regulated (50 genes) or down-regulated (17 
genes) by both SHH and PDGF-BB in a cyclopamine-inhibitable manner in KMCH-1 cells via 
an Affymetrix U133 Plus 2.0 GeneChip analysis (Table 6). 
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Figure 10.   PDGF-BB induces SMO trafficking to the plasma membrane resulting in GLI2 nuclear 
translocation and transcriptional activation of a GLI reporter gene. (A) HuCCT-1 cells were treated with 
vehicle, PDGF-BB (200 ng/mL) or PDGF-BB plus the PKA inhibitor H-89 (5 µM) for 2 hrs. SMO cellular 
localization was analyzed by immunocytochemistry. Note that PDGF-BB induces translocation of SMO from 
intracellular compartments (left) to the plasma membrane (yellow arrows, middle), an effect that is inhibited by 
the PKA inhibitor H-89 (right). Cells with membranes positive for SMO immunocytochemistry were counted in 
each of these conditions. Mean ± s.e.m. (n=7). (B) KMCH-1 cells were transiently transfected with a plasmid 
expressing GFP-tagged human SMO (GFP-SMO; 48h) and then treated with vehicle or PDGF-BB (200 ng/mL) 
with and without H-89 (5 µM) for 2 hrs. GFP-SMO localized at the plasma membrane was analyzed by TIRF 
microscopy and the fluorescent intensity quantified using image analysis software. Mean ± s.e.m. (n=20). 
(C)  GLI2 nuclear translocation in KMCH-1 cells was assessed by immunoblot analysis after treating the cells 
with vehicle or PDGF-BB (200 ng/mL) with and without H-89 (5 µM) for 8 hrs. Lamin B was used as loading 
control for the nuclear protein extracts. (D) KMCH-1 cells (normal, stable scrambled [scr.], or shSMO) were 
transiently transfected (24 hrs) with a reporter construct containing eight consecutive consensus GLI-binding sites 
(8x-GLI) and co-transfected with pRL-CMV. Cells were then treated as indicated with vehicle or PDGF-BB 
(200 ng/mL) with and without cyclopamine (5 µM) for 24 hrs. Both firefly and Renilla luciferase activities were 
quantified and data (firefly/Renilla luciferase activity) are expressed as fold increase over vehicle-treated cells 
transfected with the 8x-GLI/pRL-CMV reporter constructs. Mean ± s.e.m. (n=3; ***p<0.001). 
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Table 6.   Gene targets regulated by both SHH and PDGF-BB in a cyclopamine-inhibitable manner in 
KMCH-1 CCA cells (alphabetical order). Affymetrix U133 Plus 2.0 GeneChip analysis was performed. Genes 
were considered to be up-regulated when they (1) displayed significant up-regulation (P < 0.05, compared with 
the control group) upon SHH (single treatment), as well as PDGF-BB (single treatment) stimulation, and (2) 
displayed significant downregulation (P < 0.05, compared with the SHH and PDGF-BB groups, respectively) upon 
the addition of Hh inhibitor cyclopamine to the SHH as well as to the PDGF-BB treatment. Down-regulated genes 
were regulated vice versa to (1) and (2). 
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Figure 11.   BDEneu cells express Hh signaling pathway effectors. mRNA expression levels of the Hh signaling 
pathway members sonic (SHH), indian (IHH), and desert hedgehog (DHH) as well as patched-1 (PTCH1), 
smoothened (SMO) and the transcription factors glioma-associated oncogene (GLI) 1, 2, and 3 were assessed by 
qualitative RT-PCR analysis in the ErbB-2/neu transformed malignant rat cholangiocyte cell line BDEneu 
(employed in the in vivo CCA model). 18S ribosomal RNA expression is shown in the last column (bold). 
 
Hh signaling inhibition is tumor suppressive in vivo. To determine if the pro-apoptotic in vitro-
effect of Hh signaling inhibition by cyclopamine observed in co-cultures is translatable to an in 
vivo model, we employed a syngeneic rat orthotopic CCA model (BDEneu malignant cells 
injected into the liver of male Fischer 344 rats). Like human CCA, the BDEneu cells also 
express TRAIL in vivo.84-86 We confirmed that BDEneu cells express mRNA of members of 
the Hh signaling pathway, i.e. SHH, IHH, DHH, PTCH1, SMO, and GLI 1-3 (Figure 11). This 
rodent model of CCA also duplicates the desmoplasia characteristic of the human disease with 
numerous α-SMA-positive MFBs present in the stromal tumor microenvironment (Figure 12A). 
We confirmed that the tumor samples (including MFBs and CCA cells) in this in vivo model 
also richly expresses mRNA for PDGF-BB and its cognate receptor PDGFR-β as compared 
non-tumor liver tissue (Figure 12B). Moreover, PDGFR-β immunoreactivity was identified in 
CCA cells (Figure 12C), whereas PDGF-BB expression was apparent in the MFBs and at the 
margin of CCA glands (Figure 12D). Thus, this preclinical, rodent model of CCA mimics the 
characteristic features observed in human CCA tissue and cell lines. 
Next, we examined the potential therapeutic effects of the hedgehog signaling inhibitor 
cyclopamine in this in vivo model of CCA. In cyclopamine-treated animals, CCA cell apoptosis 
was increased as compared to controls. Apoptosis of CCA cells was confirmed by 
demonstrating colocalization of TUNEL-positive cells with cells displaying CK7 (a biliary 
epithelial cell marker expressed by CCA cells; Figure 12E). Consistent with the pro-apoptotic 
effects of  cyclopamine in this model,  cyclopamine also had an  effect on tumor size.  Indeed, 
tumor weight, and tumor/liver as well as tumor/body weight ratios were significantly decreased 
in  cyclopamine-treated rats (Figure 13A and B).  In addition,  animals treated  with 
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Figure 12.   Hh signaling inhibition promotes apoptosis in PDGFR-β-expressing CCA cells in vivo. 
A syngeneic rat orthotopic model of CCA (BDEneu cells; Fischer 344 rats) was employed for this examination. 
(A-D) The rodent CCA model recapitulates cellular expression patterns of α-SMA, PDGF-BB, and PDGFR-β 
observed in human CCA. (A) α-SMA protein expression (brown) in tumors of untreated tumor-bearing rats was 
examined by immunohistochemistry (counterstaining with Mayers’ Hematoxylin; photomicrograph was taken in 
600x magnification). (B) CCA and normal liver specimens of untreated tumor-bearing rats (14 days after tumor 
cell implantation into the left lateral liver lobe) were analyzed for mRNA expression of PDGF-B and PDGFR-β 
by quantitative RT-PCR. Mean ± s.e.m. (n=3). (C) PDGFR-β protein expression (brown) in tumors of untreated 
tumor-bearing rats was examined by immunohistochemistry (counterstaining with Mayers’ Hematoxylin; 
photomicrograph was taken in 600x magnification). PDGFR-β-positive CCA cell nests are surrounded by a 
paucicellular stromal matrix (counterstaining with Mayers’ Hematoxylin; photomicrograph was taken in 200x 
magnification and the inset is further magnified electronically). (D) PDGF-BB immunoreactivity (brown) was 
similarly analyzed and the most intense signal was observed in stromal cells and the tumor-stromal interface. (E) 
Apoptosis of CCA cells was assessed in tumor tissues by TUNEL staining (green) and the identity of cells 
determined by co-staining via immunohistochemistry for CK7 (a CCA marker; red) Animals were treated with 
vehicle (upper) or cyclopamine (lower; 2.5 mg/kg BW intraperitoneally daily for one week; 1st injection: 
7th post-operative day, 7th injection: 13th post-operative day). Quantitation of TUNEL- and CK7-positive cells 
(expressed as number per HPF) 14 days after CCA cell implantation demonstrated that in cyclopamine-treated 
animals CCA cell apoptosis was increased as compared to controls (bar graph). Mean ± s.e.m. (n=10). HPF, high 
power field. 
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Figure 13.   Hh signaling inhibition reduces tumor growth and metastasis in vivo. A syngeneic rat orthotopic 
model of CCA (BDEneu cells; Fischer 344 rats) was employed for this examination. In cyclopamine- (2.5 mg/kg 
BW intraperitoneally daily for one week; 1st injection: 7th post-operative day, 7th injection: 13th post-operative day) 
or vehicle-treated tumor-bearing rats (n=7 rats/group) tumor/liver/body weight and extrahepatic metastasis were 
assessed 14 days after tumor cell implantation into the left lateral liver lobe. (A) Depicted are representative 
abdominal cavities (left), explanted livers (middle), and hematoxylin/eosin sections (right) of vehicle- (upper) and 
cyclopamine-treated (lower) rats (HE staining; photomicrographs was taken in 40x magnification). Arrows 
indicate the liver tumors, while the arrowhead (insert in the upper left photomicrograph) displays a representative 
example of extrahepatic metastasis (peritoneum). N.l., normal liver; CCA, cholangiocarcinoma. (B) Changes in 
tumor weight as well as tumor/liver and tumor/body weight ratios are depicted as box-and-whisker plots showing 
lowest value, 25th percentile, median, 75th percentile, highest value, and in some cases outliers. (C) The stacked 
column plot indicates the numbers of animals with and without metastases for vehicle- and cyclopamine-treated 
groups (p = 0.068 by 2 test).  
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cyclopamine displayed no extrahepatic metastases whereas 43% of vehicle-treated animals 
had extrahepatic metastases, predominantly occurring in the greater omentum and peritoneum 
(Figure 13C, inset Figure 13A left upper). Moreoover, direct targeting of PDGF-BB signaling 
with imatinib mesylate was comparably effective in reducing tumor growth (Figure 14A-C) 
and metastasis (Figure 14D).  
 
 
Figure 14.   Imatinib administration reduces tumor growth and metastasis in vivo. A syngeneic rat orthotopic 
model of CCA (BDEneu cells; Fischer 344 rats) was employed. In imatinib (30 mg/kg BW intraperitoneally daily 
for one week;1st injection: 7th post-operative day, 7th injection: 13th post-operative day)- or vehicle-treated tumor-
bearing rats tumor/liver/body weight and extrahepatic metastasis were assessed 14 days after tumor cell 
implantation into the left lateral liver lobe. (A-C) Changes in tumor weight (A), tumor/liver (B) and tumor/body 
(C) weight ratios are depicted as bar graphs. Mean ± s.e.m., n=7. (D) The stacked column plot indicates the 
numbers of animals with and without metastases for vehicle- and imatinib-treated groups (p = 0.051 by 2 test). 
 
 
In aggregate, these data suggest that targeting the PDGFR-β/Hh signaling axis (e.g., with 
cyclopamine or imatinib mesylate) promotes CCA cell apoptosis and decreases tumor growth in an 
in vivo rodent model of CCA. Thus, these mechanistic treatment approaches might be a suitable 
adjuvant therapy to optimize the Mayo LTx protocol for CCA patients. 
 
5.2.2 Polo-like kinase 2 is a mediator of hedgehog survival signaling 
PLK1, PLK2 and PLK3 are prominently expressed in human CCA. Initially, we examined the 
expression of PLK1, PLK2 and PLK3 (due to their structural and functional divergences from 
other PLK family members, PLK4 and PLK5 were excluded from this study73, 74) in 50 CCA 
samples (25 intrahepatic and 25 extrahepatic CCA) by immunohistochemistry (Fig. 1). PLK1, 
PLK2 and PLK3 immunoreactive cells were present in the preponderance of the intrahepatic 
and extrahepatic CCA specimens (Figure 15A). Histological grading revealed that in extrahepatic 
and intrahepatic CCA samples, PLK2 was slightly less expressed than PLK1, whereas more 
cells stained  positive for  PLK2  than for PLK3  (Fig. 1B, Suppl. Fig. 1).  PLK1,  PLK2 and  
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Figure 15.   PLK proteins are abundantly expressed in human CCA. (A) PLK1 (left), PLK2 (middle) and 
PLK3 (right) expression in 25 intrahepatic (upper) and 25 extrahepatic (lower) human CCA samples was examined 
by immunohistochemistry. Photomicrographs were taken in 200x magnification. The asterisks indicate similar 
positions within the tumors as PLK immunohistochemistry was performed on neighboring slides. Note that 
predominantly tumorous glands but also some stromal cells exhibit PLK immunoreactivity (brown). 
Counterstaining was performed with hematoxylin (blue). (B) PLK1/2/3 protein expression quantitation of 
intrahapatic and extrahepatic CCA samples by histological grading (grade 0 = no protein expression, grade 4 = 
high protein expression). 
 
PLK3 expression was more pronounced in intrahepatic as compared to extrahepatic CCA and 
for PLK2 expression this difference was statistically significant (Figure 15B). In intrahepatic 
and extrahepatic CCA, predominantly cancer cells/glands stained positive for PLK proteins; 
however, some stromal cells within the tumor microenvironment also displayed PLK1, PLK2 
and PLK3 immunoreactivity. Thus, PLK1, PLK2 and PLK3 are abundantly expressed in the 
majority of human CCA specimens. 
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Figure 16.   Hh signaling inhibition reduces PLK2 expression in CCA cells. Cells were treated as indicated in 
serum-free medium with vehicle or rhSHH (500 ng/ml, 4 hrs) in the presence or absence of Hh signaling inhibitor 
cyclopamine (10 μM, 4 hrs). (A-C) Quantitative RT-PCR analysis for PLK1/2/3 mRNA expression was performed 
in the human CCA cell lines KMCH-1 (A), Mz-ChA-1 (B) and HUCCT-1 (C). Mean ± s.e.m., n=3. (D-E) 
Treatment of KMCH-1 (D), Mz-ChA-1 (E) and HUCCT-1 (F) cells was followed by immunoblot analysis for 
PLK2 protein expression (actin = loading control). 
 
PLK2 is regulated by hedgehog signaling in human CCA cells. Having confirmed an abundant 
expression of PLK 1, 2, and 3 proteins in human CCA, we next examined whether PLK 
signaling can be regulated by the Hh survival pathway as implicated by our prior genome-wide 
mRNA expression analysis in KMCH-1 CCA cells (Table 6). Consistent with this study, 
DOI:10.14753/SE.2016.1969
  51  
inhibition of Hh signaling with cyclopamine (an inhibitor of the Hh mediator smoothened) 
reduced PLK2 but not PLK1 or PLK3 mRNA expression as compared to SHH only-treated 
CCA cells (Figure 16A [KMCH-1 cells], Figure 16B [Mz-ChA-1 cells] and Figure 16C 
[HUCCT-1 cells]). This observation was confirmed on the protein level by immunoblot analysis 
for PLK2 protein expression in similarly treated CCA cells (Figure 16D [KMCH-1 cells], 
Figure 16E [Mz-ChA-1 cells] Figure 16F [HUCCT-1 cells]). Consistent with these findings, 
more specific Hh signaling inhibition with SHH neutralizing antibody 5E1 or the small 
molecule smoothened inhibitor GDC-0449 also reduced PLK2 protein expression as compared 
to SHH only-treated KMCH-1, MzChA-1 and HUCCT-1 cells (Figure 17). Thus, PLK2, but 
not PLK1 or PLK3, appears to be positively regulated by Hh signaling. 
 
Figure 17.   Protein expression of PLK2 is reduced upon various Hh inhibition approaches. Cells were treated 
as indicated in serum-free medium with vehicle or rhSHH (500 ng/ml, 4 hrs) plusminus SHH neutralizing antibody 
5E1 (10 µg/ml, 4 hrs) or smoothened inhibitor GDC-0449 (20 µM, 4 hrs). Treatment of KMCH-1 (left), Mz-ChA-
1 (middle) and HUCCT-1 (right) cells was followed by immunoblot analysis for PLK2 protein expression (actin 
= loading control). 
 
 
To further investigate how Hh signaling promotes PLK2 expression, we examined whether the 
hedgehog transcription factors GLI1, GLI2, and/or GLI3 bind to the PLK2 promoter. After 
identification of two putative GLI binding sites (site I and II) within the PLK2 promoter region  
containing  two  mismatches  compared  to the consensus  sequence  GACCACCCA 98  
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Figure 18:   GLI1 and GLI2 bind to a predicted GLI-binding site in the PLK2 promoter region. (A) Two 
putative GLI binding sites that contain two mismatches compared to the consensus sequence were identified in the 
PLK2 promoter region. Nucleotide positions were counted from the transcription start site (TSS). Positions and 
directions of both potential binding sites are illustrated by arrows (I and II). (B) KMCH-1 cells treated with rhSHH 
(500 ng/ml, 5 hrs) plusminus cyclopamine (10µM, 5 hrs) were employed for this study. Chromatin 
immunoprecipitation (ChIP) using antiserum to GLI1, GLI2, GLI3, or a sheep negative control IgG was performed, 
followed by PCR using primers flanking site I (277 bp) or site II (297) within the PLK2 promoter region. As 
positive controls, ChIP was performed using primers flanking the Bcl-2 promoter GLI-binding sites (GLI1 and 
GLI2; 147 bp), or primers flanking the GLI3 binding site within the GLI1 promoter (211 bp). 
 
 
(Figure 18A), we performed a chromatin immunoprecipitation assay in SHH-stimulated 
KMCH-1 cells (with or without cyclopamine) employing antibodies to GLI1, GLI2, and GLI3. 
Indeed, binding of GLI1 and GLI2 was exclusively observed in  SHH only-treated cells  
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Figure 19:   PLK2 inhibition is pro-apoptotic in CCA cells. (A-C) KMCH-1 (A), Mz-ChA-1 (B) and HUCCT-
1 (C) cells were treated as indicated with vehicle, PLK inhibitor BI 6727 (200 nM, 24 hrs), rhTRAIL (2.5 ng/mL, 
8 hrs), or BI 6727 (200 nM, 24 hrs) plus rhTRAIL (2.5 ng/mL, 8 hrs). Apoptosis was measured by DAPI staining 
with quantitation of apoptotic nuclei by fluorescence microscopy (left; mean ± s.e.m.; n=3) or fluorescent analysis 
of caspase-3/-7 activity (right; mean ± s.e.m.; n=5). (D) Stable scrambled, shPLK1-, shPLK2- and shPLK3-
KMCH-1 cells were treated with vehicle or  rhTRAIL (2.5 ng/mL, 8 hrs) and apoptosis was measured by DAPI 
staining with quantitation of apoptotic nuclei by fluorescence microscopy. Sensitivity to TRAIL (apoptosis ratio 
TRAIL- vs. vehicle-treated cells) was normalized to stable scrambled KMCH cells (A; mean ± s.e.m.; n=3). (E) 
PLK1/2/3 expression/knockdown in stable scrambled, shPLK1-, shPLK2- and shPLK3-KMCH-1 cells was 
assessed by immunoblot analysis (actin = loading control). Note that stable PLK3 knockdown also affects PLK2 
expression. 
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using primers that amplify site I (277 bp; Figure 18B first and second panel) but not site II (297 
bp; Figure 18B third panel). A control IgG did not yield a product additionally demonstrating 
specificity of the antisera used. As a positive control, we employed the Bcl-2 promoter which 
contains well recognized GLI1/2 binding sites 99 and the GLI1 promotor which contains well 
recognized GLI3 binding sites 100. These studies identified the expected occupation by GLI1 
and GLI2 (Bcl-2 promoter, 147 bp) as well as GLI3 (GLI1 promoter 211 bp; Figure 18B forth 
panel). Taken together, these data suggest that hedgehog signaling may directly regulate 
PLK2 expression by binding of the GLI1 and GLI2 transcription factors to the PLK2 promoter. 
 
PLK2 inhibition is pro-apoptotic in CCA cells. Next, we examined whether inhibition of Hh 
target gene PLK2 with the potent PLK inhibitor BI 6727 (volasertib) promotes (TRAIL-
induced) apoptosis in CCA cells. As measured by either cell morphology (Figure 19A-C left) 
or biochemically (Figure 19A-C right), BI 6727 and especially BI 6727 plus TRAIL 
significantly induced apoptosis in KMCH-1 (Figure 19A), Mz-ChA-1 (Figure 19B) as well as 
HUCCT-1 (Figure 19C) cells. As BI 6727 not only inhibits PLK2 but also PLK1 and PLK3,81 
we selectively silenced PLK1, PLK2, or PLK3 in KMCH-1 cells by an shRNA technique to 
more specifically investigate the effect of PLK inhibition on CCA cell apoptosis (Figure 19D; 
knockdown of PLKs was confirmed by immunoblot analysis [Figure 19E]). Stable knockdown 
of PLK2 sensitized KMCH-1 to TRAIL-induced apoptosis as compared to control KMCH-1 
cells (Figure 19D). Knocking down PLK1 and PLK3 also was also pro-apoptotic; however, this 
effect was significantly less pronounced (Figure 19D). Thus, PLK2 can mediate Hh 
cytoprotection against TRAIL-induced apoptosis in CCA cells. 
 
Pro-apoptotic effects of PLK2 inhibition are mediated by Mcl-1 degradation. We next sought 
to investigate the mechanism whereby PLK2 inhibition exerts its pro-apoptotic effects. Because 
cell cycle enzymes can regulate Mcl-1 expression 101 and Mcl-1 as well as Bcl-2 are 
downregulated by  PLK inhibition in  osteosarcoma  and esophageal  carcinoma  cells,76, 77 we 
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Figure 20.   PLK inhibition induces proteasomal degradation of Mcl-1 but not Bcl-2. (A) KMCH-1 cells were 
treated with vehicle or 200 nM BI 6727 for the indicated time intervals followed by immunoblot analysis for Mcl-
1 and Bcl-2 protein expression (actin = loading control). (B) PLK inhibition increases the protein levels of a 
proteasome resistant Mcl-1 mutant. Initially, KMCH-1 cells were either transfected (FuGENE HD, Promega, 
Madison, WI) with an enhanced green fluorescent protein (GFP) expressing construct alone (pEGFP-N1; 
Clontech, Mountain View, CA) or with the GFP construct plus the vector expressing a S peptide-tagged mutated 
human Mcl-1 at a 1:2 ratio (transfected cells were identified by expression of GFP). The human Mcl-1 mutant is 
resistant to proteasomal degradation due to sequential mutagenesis of the established Mcl-1 ubiquitination sites 
(amino acids 5, 40, 136, 194, and 197) from lysine to arginine. Subsequently, cells were treated as indicated with 
vehicle or BI 6727 (200 nM, 24 hrs) followed by immunoblot analysis for Mcl-1 and S peptide protein expression. 
Note that GFP-only transfected KMCH-1 cells only express the wild-type Mcl-1 but not the S peptide (actin = 
loading control). (C) PLK2 knockdown reduces Mcl-1 protein expression. Mcl-1 expression and PLK 1/2/3 
expression/knockdown in stable scrambled, shPLK1-, shPLK2- and shPLK3-KMCH-1 cells was assessed by 
immunoblot analysis (actin = loading control). Note that stable PLK3 knockdown also affects PLK2 expression 
giving an explanation for the reduced Mcl-1 protein expression also seen in shPLK3-KMCH-1 cells.  
 
 
explored the effect of PLK inhibition on cellular Mcl-1 and Bcl-2 protein levels. Indeed, 
BI 6727 administration rapidly decreased Mcl-1 (but not Bcl-2) protein levels in KMCH-1 cells 
(Figure 20A). To assess if decreased Mcl-1 protein levels are due to proteasomal degradation, 
we employed the potent proteasome inhibitor MG-132 or transfected KMCH-1 cells with a 
proteasome-resistant Mcl-1 mutant. Mcl-1 downregulation by BI 6727 is likely mediated by 
proteasomal degradation as MG-132 (Figure 21A [KMCH-1 cells], Figure 21B [Mz-ChA-1 
cells] and Figure 21C [HUCCT-1 cells]) or transfection with the proteasome-resistant Mcl-1 
mutant (Figure 20B) completely abrogated this effect. Moreover, inhibition of proteasomal 
degradation in the presence of BI 6727 increased Mcl-1 protein levels as compared  to  vehicle-
controls (Figure 21A and B  as  well  as Figure 20B)  suggesting  Mcl-1 
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Figure 21.   Pro-apoptotic effects of PLK2 inhibition are mediated by Mcl-1 degradation. (A-C) KMCH-1 
(A), Mz-ChA-1 (B) and HUCCT-1 (C) cells were treated as indicated with vehicle or BI 6727 (200 nM, 24hrs) in 
the absence or presence of the potent proteasome inhibitor MG-132 (1 μM, 24 hrs) followed by immunoblot 
analysis for Mcl-1 protein expression (actin = loading control). (D-F) KMCH-1 (D), Mz-ChA-1 (E) and HUCCT-
1 (F) cells were treated as indicated with vehicle or BI 6727 (200 nM, 24 hrs) in the absence or presence of MG-
132 (1 μM, 24 hrs). Apoptosis was measured by DAPI staining with quantitation of apoptotic nuclei by 
fluorescence microscopy (left; mean ± s.e.m.; n=3) or fluorescent analysis of caspase-3/-7 activity (right; mean ± 
s.e.m.; n=5). 
 
 
upregulation is an initial protective cell response to BI 6727 (which in BI 6727 only-treated 
cells is overwhelmed by proteasomal Mcl-1 degradation). Accordingly, BI 6727-treated 
KMCH-1 cells display a compensatory upregulation of Mcl-1 mRNA levels (Figure 22A). 
Consistent with these observations, MG-132 also blocked BI 6727-induced apoptosis in KMCH-1 
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Figure 22.   PLK inhibition increases Mcl-1 mRNA expression in vitro and in vivo. (A) KMCH-1 cells were 
treated as indicated with vehicle or BI 6727 (200 nM, 24 hrs) followed by quantitative RT-PCR analysis for Mcl-
1 mRNA expression. Mean ± s.e.m., n=3. (B) A syngeneic rat orthotopic CCA model (BDEneu cells; Fischer 344 
rats) was employed for this study. CCA specimens of BI 6727 (3 injections of 10 mg/kg BW intraperitoneally 
every other day; 1st injection: 7th post-operative day, 3rd injection: 11th post-operative day)- or vehicle-treated rats 
were analyzed for Mcl-1 mRNA expression by quantitative RT-PCR. Mean ± s.e.m., n=9. 
 
 
(Figure 21D), Mz-ChA-1 (Figure 21E) and HUCCT-1 (Figure 21F), cells as assessed 
morphologically (Figure 21D-F left) or biochemically (Figure 21D-F right). Moreover, stable 
knockdown of PLK2 by shRNA technique also reduced Mcl-1 protein levels as displayed by 
immunoblot analysis (Figure 20C). These data suggest that PLK2 inhibition reduces Mcl-1 
protein levels in a post-translational manner by proteasomal degradation thereby promoting 
apoptosis. 
 
PLK inhibition promotes CCA cell apoptosis and is tumor suppressive in vivo. To determine if 
the pro-apoptotic in vitro effect of PLK signaling inhibition by BI 6727 also is translatable to 
an in vivo model, weagain employed the syngeneic rat orthotopic CCA model (BDEneu 
malignant cells injected into the liver of male Fischer 344 rats).43, 69, 85, 86 First, we sought to 
further validate  this model by assessing  mRNA expression of  PLK1-3 in CCA specimens as  
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Figure 23   Effects of Hh and PLK inhibition are recapitulated in vivo. The syngeneic rat orthotopic CCA 
model (BDEneu cells; Fischer 344 rats) was employed for this study. (A) CCA and normal liver specimens of 
untreated rats were analyzed for mRNA expression of PLK1 (left), PLK2 (middle) and PLK3 (right) by 
quantitative RT-PCR. Mean ± s.e.m., n=3. (B) CCA specimens of cyclopamine (2.5 mg/kg BW intraperitoneally 
daily for one week; 1st injection: 7th post-operative day, 7th injection: 13th post-operative day)- or vehicle-treated 
rats were analyzed for PLK2 (green) expression of tumor cells (identified via co-staining for CCA cell marker 
cytokeratin 7 [CK7]; red) by immunofluorescence microscopy. Merged images depict colocalized CK7/PLK2 
protein expression in yellow (green-red overlay). PLK2 immunoreactivity in CCA cells was quantitated using the 
software ImageJ 1.44o (B lower; mean ± s.e.m., n=7). (C) CCA specimens of BI 6727 (3 injections of 10mg/kg BW 
intraperitoneally every other day; 1st injection: 7th post-operative day, 3rd injection: 11th post-operative day)- or 
vehicle-treated rats were analyzed for Mcl-1 (green) expression of CCA cells (similar CK7 co-staining and 
quantitation [mean ± s.e.m., n=9] as in B). (D) Apoptotic nuclei were assessed in CCA samples of vehicle (left 
photomicrograph)- and BI 6727 (right photomicrograph)-treated rats by TUNEL staining (green) and the identity 
of TUNEL-positive cells confirmed by CK7 co-staining (red). Quantitation of TUNEL-positive cells (expressed 
as number per high power field [HPF], D left) demonstrates that in BI 6727-treated animals, CCA cell apoptosis 
was increased as compared to controls (mean ± s.e.m., n=9). In all photomicrographs nuclei are counterstained 
with DAPI (blue) and CCA glands within the tumor stroma are illustrated by white dotted lines. 
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compared to normal rat liver tissue via quantitative RT-PCR. PLK2 mRNA levels in CCA were 
significantly higher as compared to normal rat livers (Figure 23A). On the protein level, PLK2, 
similar to the human disease (Figure 15), was abundantly expressed in tumorous glands 
(identified by cytokeratin 7 [CK7] co-staining; CK7 is a biliary epithelial cell marker expressed 
by CCA cells) and also by occasional stromal cells within the tumor microenvironment (Figure 
23B). Administration of Hh inhibitor cyclopamine significantly decreased PLK2 expression in 
tumorous glands (dotted lines) but not stromal cells in this in vivo CCA model (Figure 23B 
middle photomicrographs and bar graph). Also consistent with our in vitro observations, 
treatment with PLK inhibitor BI 6727 in vivo reduced Mcl-1 protein expression in CCA cells 
(Figure 23C middle photomicrographs and bar graph). PLK2 mRNA levels were also increased 
in CCA specimens of BI 6727-treated rats as compared to controls (Figure 22B). Finally, CCA 
cell apoptosis was increased in animals treated with BI 6727 as compared to vehicle-treated rats 
(Figure 23D; CCA cell apoptosis was confirmed by demonstrating colocalization of 
TUNEL-positive cell nests with tumorous glands displaying CK7). Thus, this preclinical rodent 
model of CCA recapitulates characteristic features observed in human CCA tissue and in vitro 
studies including the pro-apoptotic effect of PLK inhibition on CCA cells. 
Consistent with the pro-apoptotic effects of PLK2 observed in the CCA in vivo model, PLK2 
was also effective in reducing tumor size and metastasis (Figure 24A-F). Indeed, tumor weight 
and tumor/liver weight ratios were significantly decreased in BI 6727-treated rats (Figure 24A-
E). Additionally, 100% of the rats treated with BI 6727 displayed no extrahepatic metastases, 
whereas only 56% of the vehicle-treated animals were free of metastases (four out of nine 
animals in this group showed tumors predominantly occurring in the greater omentum and 
peritoneum; Figure 24A [lower right photomicrograph] and F). Taken together, these data 
suggest that BI 6727 decreases tumor growth as well as metastasis in an in vivo rodent model 
of CCA. Thus, this mechanistic treatment strategy might also be an eligible accompanying therapy 
to optimize the Mayo LTx protocol for CCA patients. 
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Figure 24.   PLK inhibition is tumor suppressive in vivo. The syngeneic rat orthotopic model of CCA (BDEneu 
cells; Fischer 344 rats) was employed for this study. In BI 6727 (3 injections of 10mg/kg BW intraperitoneally every 
other day; 1st injection: 7th post-operative day, 3rd injection: 11th post-operative day)- or vehicle-treated rats 
tumor/liver/body weight and extrahepatic metastasis were assessed 13 days after tumor cell implantation into the 
left lateral liver lobe. (A and B) Representative photomicrographs display explanted livers (left upper), gross 
pathological tumor appearance within the livers (right upper), extirpated tumors with scale (left lower), and the 
abdominal cavity (right lower) of vehicle (A)- or BI 6727 (B)-treated rats (arrows indicate liver tumors and 
arrowheads extrahepatic metastases). (C-E) Changes in tumor weight (C), tumor/liver weight ratios (D), and 
tumor/body weight ratios (E) are depicted as bar graphs. Mean ± s.e.m., n=9. (F) The stacked column plot indicates 
the numbers of animals with and without extrahepatic metastases for the vehicle- and BI 6727-treated group 
(p < 0.05 by 2 test). 
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6 DISCUSSION 
6.1 General Optimization Approaches For Liver Transplantation 
6.1.1 Preservation solution/chloride study 
The present in vivo study performed with a chloride-poor and a chloride-containing variant of 
a new HTK-based preservation solution suggests that beneficial effects of chloride-containing 
media on the endothelium/microcirculation overbalances chloride-dependent cold storage 
injury of hepatocytes. 
 
The new preservation solution. Taking into account new findings on the mechanisms of initial 
preservation injury triggered by hypoxia,5, 6, 8, 102-106 hypothermia,7, 9, 10, 18, 19, 21, 107-110 
preservation solution toxicity,11, 12 and inflammatory processes,7, 13, 14 a new HTK-based 
preservation solution was developed.15 The amino acids glycine and alanine were incorporated 
into the new solution in order to attenuate hypoxic cell injury, in which increased intracellular 
sodium plays a crucial role.5, 103-106 Previous studies have shown that glycine provides 
protection from hypoxic injury by preventing the formation of nonspecific leaks for small ions 
including sodium.106 In addition, several studies demonstrated that Kupffer cell activation 
triggered by organ manipulation can be inhibited by glycine.111-113 Alanine, structurally related 
to glycine, seems to exert similar inhibitory effects on intracellular sodium accumulation 
induced by hypoxia.106 It has been shown to inhibit hypoxic injury to isolated hepatocytes 106, 
114 and to improve recovery of the liver exposed to cold ischemia and reperfusion.115 
In previous in vitro experiments we showed that histidine (serving as buffer; pKa = 6.2 at 20 °C) 
can be toxic due to an iron-dependent formation of reactive oxygen species.12 Therefore, 
histidine, the only buffer in HTK solution, was partly (in confines given by charge) replaced by 
the nearly non-toxic N-acetylhistidine, which possesses comparable buffering power (pKa = 7.2 
at 20 °C). Aspartate was added to the new solution together with α-ketoglutarate to allow 
replenishment of the citric acid cycle (after transamination) and to improve energy state 116, 
arginine serves as substrate for NO synthase, thus counteracting postischemic sinusoidal 
constriction.117-119 Enhanced NO levels also can improve bile production120 and decrease 
necrotic as well as apoptotic cell death.121 Since mannitol might permeate the membrane of 
hepatocytes causing cell swelling122, 123 it was replaced by sucrose.  
In this composition, the new preservation solution was already shown to attenuate preservation 
injury to isolated perfused rat livers compared to HTK.15 In order to obtain a chloride-
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containing variant of the new solution for the present study (with 34.04 mmol/l to be the highest 
possible chloride concentration without altering inorganic cation concentrations or further 
decreasing organic anions), additional slight modifications − mainly affecting the 
concentrations of N-acetylhistidine (partly anionic), histidine (partly cationic) and 
sucrose − became necessary for reasons of charge and osmolarity. In the future it is planned to 
supplement the new base solution with iron chelators, which should inhibit cold-induced cell 
injury and further attenuate histidine toxicity (transplant studies testing the new preservation 
solution with the iron chelators deferoxamine and LK 614, which proved beneficial in isolated 
perfused organs,124-126 are currently under way); however, here, we intended to optimize the 
base solution and did not yet add iron chelators. 
 
Chloride and cold-induced injury in vitro. The effects of extracellular chloride on cold-induced 
injury are dissimilar in cultures with different cell types. Isolated hepatocytes from Wistar rats suffer 
cold storage injury in cell culture media/preservation solutions that contain chloride at 
concentrations above 40 to 50 mmol/l due to an entity preliminarily characterized by us as iron-
independent cold-induced injury.22 How physiological extracellular chloride concentrations 
contribute to cell death of hepatocytes under hypothermic conditions is currently unclear. A likely 
explanation can be adverse effects of chloride on cellular pH regulation. Influences on apoptotic 
processes may represent another possibility, since two studies suggested extracellular chloride to 
promote apoptosis via interference with a receptor-mediated pore formation127 and the early 
intrinsic apoptotic pathway,128 respectively. 
In contrast to that, cold-stored porcine aortic endothelial cells, and endothelium of intact porcine 
aortic segments benefit from chloride-containing preservation solutions as shown by improved 
cell survival rates.23, 24 Again, the mechanism of action is currently unclear. 
 
Chloride and hypoxic injury in vitro. The impact of chloride on hypoxic cell injury has been 
discussed controversially. In the pathogenesis of hypoxic injury to hepatocytes, rising cytosolic 
sodium concentrations play a crucial role5, 103-106 − a process that can be inhibited by the amino 
acid glycine.106, 129 Carini et al. proposed that the protective effect of glycine results from 
inhibition of glycine-sensitive ligand-gated chloride channels and concluded that chloride 
influx might be coupled with intracellular sodium accumulation.129 In their experiments 
chloride-poor media attenuated intracellular sodium accumulation and improved cell viability.  
In contrast to that, a study of Frank et al. demonstrated glycine to be even protective in a 
chloride-free medium while a chloride-free medium itself did not inhibit hypoxic injury at all.106 
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This apparent discrepancy may be due to the usage of cultured hepatocytes in the latter study, 
while Carini et al. performed their experiments with isolated hepatocytes in suspension; the use 
of a cell suspension may, for instance, result in a more pronounced hypoxia-induced 
acidification leading to better antagonization of an injurious alkalinization by chloride-free 
conditions.130 Frank et al. suggested sodium influx and hypoxic cell injury to be chloride-
independent and rather to be related to the formation of nonspecific ion leaks.106 
Chloride and preservation injury in vivo. With the chloride-containing preservation solution, 
sinusoidal perfusion rates as well as blood flow velocities in sinusoids and postsinusoidal 
venules were significantly improved after LTx. This is consistent with our in vitro data 
demonstrating beneficial effects of chloride on endothelial cell survival.23 It can be speculated 
whether the improved microcirculation and the tendency of vasodilation seen in postsinusoidal 
venules with chloride is due to a less impaired endothelial dysfunction leading to increased NO 
levels and/or a better NO response since increased NO formation is sufficient to improve 
hepatic tissue blood flow after reperfusion as shown by laser flowmetry.118 
It is not necessarily a contradiction that previous in vitro experiments found cold-stored rat 
hepatocytes to be harmed by extracellular chloride,22 but here a slight decrease of serum 
transaminase and LDH activities in rats after LTx with the chloride-containing solution was 
observed (Fig. 3A). First, the injurious effects of chloride become evident mainly at chloride 
concentrations exceeding 40-50 mmol/l.22 Moreover, the beneficial effect of chloride on 
hepatocytes in transplanted rat livers is possibly a consequence of the clearly improved 
microcirculation following reperfusion. Thus, chloride-containing media might be 
advantageous for hepatocytes due to an indirect effect in vivo. 
As a consequence of both, the direct advantageous effect of chloride on the endothelium and 
the possibly indirect beneficial effect of chloride on parenchymal cells, bile flow − a reliable 
indicator of energy-dependent liver function131, 132 − and survival were shown to be improved. 
It must be emphasized that survival represents the study criterion with the highest medical 
relevance and therefore was tested in three different series. In these series the broad range of 
potential clinical situations was reflected by LTx protocols with different combinations of cold 
ischemic and warm ischemic injury as well as surgical trauma and genetic 
background/immunological influences. In all experimental series, survival rates after LTx with 
the chloride-containing variant of the new solution were increased. At first view, these results 
might appear counterintuitive as UW solution (or Viaspan), which greatly improved liver 
preservation in comparison to the chloride-containing (15 mM chloride) Euro-Collins 
solution133 and which appears to yield results largely equivalent to HTK solution,134, 135 provides 
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good liver preservation despite the absence of chloride. This good preservation, however, might 
also be due to the other components of UW solution that largely differ from these other two 
solutions. That in one study with a modified, sodium-rich UW solution an injurious effect of 
chloride was observed136 is also not necessarily contradictory with regards to the known role of 
a sodium influx in hypoxic injury (see above), that might be accompanied by a chloride influx. 
Thus, the effects of chloride might differ in sodium-rich vs. sodium-poor preservation solutions. 
Whether also the potassium-rich UW solution or other preservation solutions would become 
more protective for the endothelium with the incorporation of chloride remains to be 
established. 
The data shown here suggest that chloride concentrations in HTK-based (and possibly also 
other) preservation solutions for LTx should not be too low (in confines given by toxicity for 
hepatocytes) in order to provide protection to endothelial cells since these cells are likely to be 
more sensitive to cold-induced injury than hepatocytes. This is in accordance with various 
studies describing a comparably higher loss of non-parenchymal cell viability after cold 
storage/reperfusion as assessed by nuclear trypan blue uptake, LDH release, electron 
microscopy, and TUNEL assay.3, 137-141 One reason for the higher susceptibility of endothelial 
cells to cold-induced injury may be their reduced antioxidant status in comparison with 
hepatocytes.142, 143 
As already mentioned above, the addition of iron chelators can be expected to further improve 
protection from cold-induced cell injury and to further inhibit histidine toxicity.7, 12, 18, 19 Studies 
comparing the new (chloride-containing) solution supplemented with the well-known iron 
chelator deferoxamine and the new, more membrane-permeable iron chelator LK 614 126 to 
HTK solution have shown further improvement in rat liver preservation126 and attenuation of 
lipid peroxidation, serum liver enzyme activities and histological damage in isolated perfused 
marginal livers from non-heart beating rat donors.124 Similarly, this solution ameliorated liver 
injury after hypothermic machine preservation of marginal rat liver grafts when compared to 
HTK solution.125 Finally, the modified HTK-based preservation solution tested here is non-
toxic, 15 and its physical characteristics as well as its use are similar to traditional HTK solution 
(e.g. it can be used without flush-out, unpublished results). 
 
6.1.2 Erythropoietin study 
In this in vivo study, we demonstrated that EPO treatment induces a proliferative response in 
hepatocytes resulting in an increased LBWR before and especially after pLTx. This is 
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associated with an increased overall survival. The underlying mechanisms of these beneficial 
effects include an increased expression of the pro-regenerative mediator c-jun as well as the 
blockage of apoptotic pathways by upregulation of the anti-apoptotic gene Bcl-XL.  
 
In our preconditioning experiments we have demonstrated that EPO treatment can raise the 
LBWR and Ki-67-proliferation index of normal (donor) livers. Still, one of the major concerns 
in using exogenous mitogens is that the preoperative stimulus during preconditioning results in 
suppression of regeneration after surgery. Data from Malik et al. and our group, however, 
suggest that the DNA synthetic response of the hepatocytes is not changed after treatment with 
the mitogen tri-iodothyronine.28, 144 These results indicate that a larger remnant size and the 
resulting reduced volume deficit after PH caused by exogenous stimuli does not inevitably 
result in a diminished stimulation of regeneration. In addition, EPO did not impair the 
regenerative response after surgery, since rats that were treated with additional EPO 
perioperatively showed an increased remnant liver mass and a higher Ki-67 proliferation index 
after pLTx. The dose of EPO used in our experiment was not much higher than employed in 
clinical practice (i.e., only 10 times higher than doses applied in bone marrow transplants).  
 
Unexpectedly, EPO-treatment did not significantly improve laboratory parameters after pLTx. In 
contrast, Sepodes et al. could demonstrate an advantageous effect of EPO-preconditioning on 
serum parameters in their ischemia-reperfusion experiments, possibly by reducing the oxidative 
stress and caspase-3 activation, suggesting the subsequent reduction of apoptosis.145 Despite the 
lack of positive effects on laboratory parameters, preconditioning with EPO significantly 
improved overall survival following pLTx.  
 
Malik et al. demonstrated a beneficial effect of exogenously administered tri-iodothyronine on 
the regenerative response of the liver following PH.146 The authors suggest a synergistic effect 
of two distinct liver growth pathways: direct hyperplasia and compensatory regeneration. In our 
experiments, 24 h following pLTx, EPO mediated amplifications of regeneration pathways 
including c-jun signaling seems to be more likely. C-jun is an important mediator of the EPO 
signaling transduction cascade.147, 148 During liver regeneration c-jun may be activated by EGF- 
and HGF-dependent signaling cascades.149 Together with the c-fos gene, which is induced via 
TNF-α, NF-κB, IL-6 and STAT 3, 150 it forms the AP-1 complex. C-jun then seems to exert its 
proliferative effects by regulating the cell cycle via p53/p21-, cyclin D1- and PCNA-dependent 
pathways. 151-154. The importance of c-jun for cells to exit from p53-imposed growth arrest 
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already was described by Shaulian et al.153 Moreover, the role of c-jun for liver regeneration after 
PH and during perinatal/postnatal liver development is not only of theoretical nature since various 
knock-out experiments could reveal detrimental consequences if this gene is lacking.149, 155 
 
In a model of cardiac injury, Calvillo et al. reported that EPO prevents the majority of cells from 
apoptosis.156 We therefore investigated whether EPO can protect hepatocytes from apoptosis 24h 
after pLTx and were able to show that EPO-treated animals exhibit a lower proportion of 
apoptotic cells. In addition, the anti-apoptotic gene Bcl-XL was significantly upregulated. Further 
findings concerning EPO and apoptosis have been reported for the central nervous system, 
suggesting a specific anti-apoptotic effect of EPO in non-hematopoietic cells.157, 158. Moreover, 
it has been demonstrated that EPO reduces cell death in cultured human proximal tubular cells, 
too.159 
Interestingly, c-jun is also involved in the complex regulation of apoptosis. Jacobs-Helber et al. 
reported that c-jun has the potential to hamper erythroid cells from entering apoptosis.147 In 
further knock-out experiments and studies with mice models of HCC it was demonstrated that 
this anti-apoptotic effect is partially mediated by crosstalk with NF-κB signaling as well as by 
antagonizing p53 activity 154, 160, 161. However, c-jun is part of pro-apoptotic pathways as well.162 
 
Although EPO has also been described as a proangiogenetic factor, 32, 33 there was no evidence 
for such an effect in our experiments. Administration of EPO also had no impact on the 
hematocrit level within the first 48h, implying that its beneficial effects are not mediated by this 
component. Interestingly, despite several injections with high EPO doses, EPO-receptor mRNA 
was not considerably downregulated suggesting that there was no development of an early 
tolerance in our model. 
 
By stimulating cell proliferation and downregulating apoptotic pathways, EPO may also have a 
procancerogenic potential, especially in the setting of its clinical use in oncologic patients 
(e.g., LTx due to HCC or CCA). It remains to be determined whether short-term therapy before 
and after surgery would have such an effect. Therefore, further studies have to be carried out in 
order to investigate this important aspect more precisely. However, EPO is already widely used 
for the prevention and treatment of anemia resulting from cancer chemotherapy and recent studies 
show that at least in leukemia and breast cancer EPO fails to stimulate a cancerous 
proliferation.163 
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6.2 Optimization Of Liver Transplantation For Cholangiocarcinoma 
6.2.1 Myofibroblast-derived PDGF-BB/hedgehog signaling study 
The results of this study provide new mechanistic insights regarding cytoprotective MFB-to-
tumor cell paracrine signaling in CCA. These data indicate that MFB-derived PDGF-BB (1) 
protects CCA cells from TRAIL-induced cell death in vitro; (2) exerts this cytoprotection in a 
Hh signaling-dependent manner by inducing cAMP/PKA-mediated SMO trafficking to the 
plasma membrane resulting in GLI2 nuclear translocation and GLI transcriptional activity; (3) 
and appears to act similarly in a rodent in vivo-model of CCA, where PDGF-BB/Hh signaling 
inhibition by imatinib mesylate or cyclopamine promotes CCA cell apoptosis and is tumor 
suppressive. These findings are illustrated in Figure 25 and discussed in greater detail below. 
 
In this study, we explored a role for PDGF-BB as a MFB-derived survival factor for CCA cells. 
Indeed, in coculture experiments, MFB cytoprotection against TRAIL-induced apoptosis was 
abrogated by neutralizing antisera to PDGF-BB suggesting MFB-derived PDGF-BB is a potent 
anti-TRAIL survival factor for CCA cells. Although many cancer cells may not express PDGF 
receptors,96 our data indicate CCA cells express PDGFR-β and respond to PDGF-BB by 
activating this receptor (phosphorylation). These observations suggest the existence of a 
distinctive paracrine survival signaling pathway between MFB and CCA cells.  
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Figure 25.   Schematic diagram illustrating the role of platelet-derived growth factor (PDGF)-BB in 
promoting apoptosis resistance in cholangiocarcinoma (CCA) cells. PDGF-BB, mainly secreted by 
myofibroblasts (MBFs), promotes hedgehog (Hh) signaling by inducing trafficking of Hh signaling mediator 
smoothened (SMO) to the plasma membrane with subsequent glioma-associated oncogene (GLI) activation 
resulting in apoptosis resistance. PDGF-BB/Hh signaling inhibitors such as imatinib mesylate/cyclopamine block 
Hh survival signaling and, thus, promote apoptosis in CCA cells. TRAIL; tumor necrosis factor-related apoptosis-
inducing ligand. 
 
Coactivation networks are being increasingly recognized in cancer biology.164 We had 
previously implicated a major role for Hh-signaling directed survival signals against TRAIL 
cytotoxicity of CCA cells in vitro. 67, 68 Also, others have suggested PDGF-BB increases Hh 
ligand generation in immature bile ductular cells.58 Given this information, we posited that a 
PDGF-BB and Hh signaling co-activation network could contribute to survival signaling in 
CCA cells. Somewhat surprisingly, we found that PDGF-BB does not induce Hh ligand 
expression. 57, 58 Instead, PDGF-BB appears to increase Hh signaling by promoting SMO 
trafficking to the plasma membrane (an event known to increase SMO activation 64). 
Moreover, these processes were blocked by H89 (an inhibitor of the cAMP-regulated kinase 
PKA), suggesting that PDGF-BB-induced SMO trafficking is PKA-mediated. We note that 
the role of PKA in the Hh pathway is complex and likely depends upon the cell type and 
cellular context. For example, although PKA has been reported to promote Hh signaling at 
the level of SMO, it may act as a negative regulator by promoting the cleavage of GLI proteins 
into their repressor forms. 64 However, in CCA cells treated with PDGF-BB, PKA does not 
repress PDGF-BB-mediated GLI transcriptional activity as we observed activation of a GLI 
reporter gene assay, and common gene expression between SHH and PDGF-BB stimulation 
in a cyclopamine-inhibitable manner. 
 
Because receptor tyrosine kinases - as opposed to G-protein coupled receptors - do not directly 
stimulate adenylate cyclase (the enzyme generating cAMP), the mechanism by which PDGFR-
β signaling enhances PKA activity in CCA cells will require further elucidation. A plausible 
mechanism would be the PDGF-BB/mitogen-activated protein kinase (MAPK)/prostaglandin 
E2/cAMP axis described in arterial smooth muscle cells. 165 
 
The SMO inhibitor, cyclopamine, and the PDGFR inhibitor, imatinib mesylate, also achieved 
suppression of CCA tumor growth in a preclinical rodent model of CCA as single agents. The 
orthotopic rodent model of CCA employed in these studies reflects a similar molecular 
signature and TRAIL expression as human CCA, 85, 86 exhibits a tumor microenvironment rich 
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in activated α-SMA-secreting MFBs, and also recapitulates the cellular expression patterns of 
PDGF-BB and PDGFR-β found in many human CCA samples.  
Berman et al. also reported cyclopamine suppresses digestive tract tumors including CCA in 
vivo (in a xenograft tumor model).61 Herein, we expand this observation and provide evidence 
of functional interactions between tumor microenvironment and CCA cells. Moreover, we 
demonstrate that Hh signaling inhibition increases apoptosis of CCA cells in vivo. The 
mechanism by which cyclopamine induces apoptosis in vivo likely involves TRAIL expression 
in the tumor tissue, because cyclopamine does not increase apoptosis of monocultured CCA 
cells in the absence of TRAIL. Hh signaling has also been implicated in altering the tumor 
microenvironment.166 For example, Hh inhibitors increase the efficiency of cytotoxic 
chemotherapy in rodent models of pancreatic cancer by modulating the microenvironment of 
the cancer.54 In contrast to those studies, we did not observe a decrease in α-SMA positive 
MFBs in cyclopamine treated tumors (data not shown). Moreover, the importance of Hh 
signaling in cancer cells as opposed to stromal cells has recently been emphasized. 167 Our 
observations are most consistent with a direct effect of cyclopamine on the tumor cells in vivo, 
although we cannot fully exclude a non-cytotoxic effect of cyclopamine on MFB function.  
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6.2.2 Hedgehog signaling/Polo-like kinase 2 study 
This study provides new mechanistic insights regarding a Hh and PLK signaling co-activation 
network in CCA. These data indicate that (1) Hh signaling directly regulates PLK2 mRNA and 
protein expression; (2) PLK2 promotes Mcl-1 stabilization providing resistance to cell death by 
TRAIL; and (3) PLK inhibition is tumor suppressive in an orthotopic syngeneic rodent in vivo 
CCA model. These findings are illustrated in Figure 26 and discussed in greater detail below. 
 
In the prior study, we reported that MFB-to-cancer cell paracrine signaling imparts survival 
signals for CCA by co-activation of the Hh signaling pathway. Indeed, Hh signaling inhibition 
by cyclopamine increased the susceptibility of CCA cells to apoptotic stimuli. Moreover, a 
microarray mRNA expression analysis also suggested Hh signaling positively regulates cell 
cycle enzyme PLK2 in CCA cells (Table 6). Therefore, we further examined PLK2 regulation 
by Hh signaling and explored whether targeting of PLK2 signaling would be similarly effective 
in restoring CCA cell susceptibility to TRAIL-induced apoptosis. As cancer cells frequently  
develop  resistance  to  smoothened   inhibitors, 168, 169  blocking  PLK2  may  
 
 
Figure 26.   Schematic diagram illustrating the role of Hh and PLK2 signaling in promoting CCA cell 
resistance to endogenous TRAIL cytotoxicity via stabilization of anti-apoptotic Mcl-1. Hedgehog 
(Hh)/Smoothened or (Polo-like kinase) PLK inhibitors such as cyclopamine or BI 6727 block Hh/PLK2 survival 
signaling and, thus, promote apoptosis in CCA cells. GLI, glioma-associated oncogene; Mcl-1, myeloid cell 
leukemia-1; TRAIL; tumor necrosis factor-related apoptosis-inducing ligand.  
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be a promising new therapeutic approach for targeting this cancer survival pathway downstream 
of smoothened. In vitro, PLK2 was found to be directly regulated by the Hh pathway. PLK2 
cytoprotection against TRAIL-induced apoptosis was abrogated in the presence of PLK 
inhibitor BI 6727 or when PLK2 was selectively knocked down in KMCH-1 cells. Moreover, 
PLK2-mediated cytoprotection was, at least in part, due to stabilization of Mcl-1, a crucial 
survival factor for CCA.78-80 These observations suggest that PLK2 represents an important link 
between Hh survival signaling and Mcl-1 protein expression in CCA cells. Thus, PLK 
inhibition might be a promising strategy for the multimodal treatment of CCA including the 
Mayo LTx protocol. 
 
The effect of PLK inhibition on CCA cell viability has also been investigated in a single prior 
study.170 In their in vitro study, Thrum et al. reported that PLK inhibition reduces CCA cell 
proliferation. Herein, we expand the effects of PLK inhibition by demonstrating that it also is 
pro-apoptotic in vitro and in vivo. Moreover, we demonstrate that selective PLK2 inhibition has 
a more pronounced pro-apoptotic effect than selective PLK1 or PLK3 inhibition in CCA cells.  
Other than PLK2 or PLK3, PLK1 has been intensively studied and is also a potential target for 
anti cancer therapy in other cell types.74 The roles of PLK2 and PLK3 are less well understood 
and studies in haematologic diseases assume PLK2 and PLK3 act as tumor suppressors through 
their interactions with p53 signaling.74, 171 Consistent with these observations PLK 2 and PLK3 
are minimally expressed in various human tumors.172 In CCA cells, however, PLK2 (and 
perhaps PLK3) appears to have a cytoprotective function, which likely explanes their abundant 
expression in human and rodent CCA specimens. Like MET, NF-κB, β-Cantenin, Jnk, Shp 2 
and Stat3, PLK2 (and PLK3), thus, might belong to the emerging group of molecules that seem 
to have conflicting tumor-suppressive and oncogenic roles in carcinogenesis depending on 
tumor type and state of tumor development.173  
 
The orthotopic, syngeneic rodent CCA model used in the present study recapitulates the 
molecular signature and TRAIL expression of human CCA as discussed above. It also provides 
a syngeneic tumor microenvironment avoiding problems of immunocompromise and tumor-
stromal incompatibilities problematic in human xenograft models and mimics the cellular 
expression patterns of PLK2 found in the human disease. Moreover, the BDEneu CCA cells 
injected into the rat livers express all relevant Hh signaling pathway factors as shown before 
(Figure 11). In the prior study employing this in vivo model, Hh signaling inhibition with 
smoothened inhibitor cyclopamine was reported to induce CCA cell death and inhibit tumor 
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growth. In the present study, we extend these prior observations by demonstrating that Hh 
inhibition also reduces PLK2 protein expression in vivo. In addition, we show that PLK 
inhibition leads to a decrease in Mcl-1 protein expression in CCA cells also resulting in CCA 
cell apoptosis and reduced tumor growth in vivo. Our in vitro observations are most consistent 
with the pro-apoptotic and tumor-suppressive in vivo effects of BI 6727 mainly being mediated 
by PLK2 inhibition; however, at this point we cannot completely exclude a contribution of 
PLK1 and PLK3 inhibition to the effects seen in BI 6727-treated animals. 
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7 CONCLUSIONS 
The observations from the studies presented suggest that: 
1. In vivo beneficial effects of chloride-containing preservation solutions on the 
endothelium/microcirculation exceed chloride-dependent hepatocyte injury occurring 
during cold storage. Therefore, HTK-based and possibly other preservation solutions 
for liver (and vessel) grafts should contain chloride.  
2. Erythropoietin treatment significantly improves liver regeneration and survival after 
pLTx, in part, by upregulation of pro-regenerative mediator c-jun as well as the anti-
apoptotic gene Bcl-XL. Thus, EPO application may represent a promising adjuvant 
strategy to optimize the clinical outcome especially after sLTx and LDLT. 
3. MFB-derived PDGF-BB protects CCA cells from TRAIL cytotoxicity by a Hh 
signaling–dependent process. Targeting PDGFR-β and/or Hh signaling sensitizes these 
tumor cells to apoptotic cell death. Therefore, these results might have therapeutical 
implications for the pretreatment of patients awaiting LTx for CCA. 
4. PLK2 appears to be a pivotal mediator of Hh survival signaling in CCA cells. Targeting 
the Hh/PLK signaling co-activation network also sensitizes CCA cells to apoptosis. 
Thus, besides Hh inhibitors, PLK inhibitors might be of therapeutic value for the 
multimodal treatment of human CCA including the Mayo LTx protocol. 
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8 SUMMARY 
INTRODUCTION. Liver transplantation (LTx) is a viable treatment option of end-stage liver 
diseases including neoplasms like cholangiocellular carcinoma (CCA). However, various new 
insights regarding preservation injury, regeneration and apoptosis mechanisms of normal 
hepatocytes and CCA tumor cells are not considered by established LTx procedures yet. 
OBJECTIVES. The present studies aimed to develop different adjuvant mechanistic therapies 
suitable for LTx optimization in general terms and regarding the multimodal LTx concept of 
the Mayo protocol for CCA patients. METHODS. We tested a new preservation solution with 
different chloride concentrations, erythropoietin (EPO) as well as platelet-derived growth factor 
(PDGF)-BB, hedgehog (Hh), or polo-like kinase (PLK)2 inhibitors for these purposes. We 
employed a full size and partial (30%, pLTx) rat LTx model as well as a syngeneic rat orthotopic 
CCA model in addition to human CCA samples as well as the human CCA cell lines 
KMCH-1/HUCCT-1/Mz-CHA-1 and human myofibroblastic (MFB) LX-2 cells for these 
studies. RESULTS. The new chloride-containing preservation solution improved rat overall 
survival by beneficial effects on microcirculation in sinusoids and postsinusoidal venules. EPO 
increased liver growth in unresected (donor) and pLTx recipient rats. Moreover, apoptosis 
clearly was reduced in pLTX liver grafts accompanied by longer recipient overall survival rates. 
The EPO effects, in part, were mediated by upregulation of the pro-regenerative c-jun and the 
anti-apoptotic Bcl-XL gene. In the CCA-specific studies, targeting PDGF-BB or Hh signaling 
rendered CCA cells sensitive to apoptosis due to blockage of a Hh-dependent and MFB-derived 
protective effect of PDGF-BB. Additionally, PLK2 was identified as an important mediator of 
Hh survival signalling and PLK inhibition also proved to be pro-apoptotic. CONCLUSIONS. 
The present findings might be of therapeutic value for LTx procedures in general as well as the 
multimodal Mayo LTx protocol for CCA patients. 
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9 ÖSSZEFOGLALÓ 
BEVEZETÉS. A májátültetés (LTx) ma már világszerte elfogadott eljárás a végállapotú májbetegségek, 
többek között a hepatocellularis  carcinoma és szelektált esetekben a cholangiocelluláris carcinoma 
(CCA) kezelésére. Általánosan megfigyelhető új tendencia, hogy egyre több kiterjesztett kritériummal 
bíró májgraft (ECD-extended criteria donor) kerül beültetésre a donorok életkorának eltolódása miatt. 
A máj prezervációs ártalmai ezáltal új jelentőséggel bírnak és a beültetést követő iszkémiás-reperfúziós 
károsodás további kutatása is kiemelt fontosságú. Emiatt is időszerű, hogy a prezervációs károsodással 
kapcsolatos ismeretanyagokat átértékeljük és új elemekkel egészítsük ki. A daganatos beteségek miatt 
végzett májátültetések köre is bővül. Ide tartoznak az irreszekábilis cholangiocelluláris carcinoma 
szelektált esetei, ahol a pár évvel korábban bevezetett Mayo-protokoll átértékelése és kibővítése is 
aktuális. CÉLKITŰZÉSEK. A jelen tanulmány célja az eddig alkalmazott máj graft prezervációs 
eljárások vizsgálata, elemzése és új elemekkel történő kiegészítése. Továbbá olyan új lehetőségek 
kidolgozása, melyek hozzásegíthetnek a májátültetés további fejlődéséhez és sikerességéhez a 
multimodális Mayo protokoll szerint kezelt CCA betegeknél. MÓDSZEREK. Megvizsgáltunk egy új 
prezervációs oldatot eltérő klorid koncentrációval, elemeztük az eritropoetin, a „platelet-derived growth 
factor” (PDGF)-BB, a „hedgehog” (Hh)és a „poli-like kinase” (PLK)2 hatását a máj graft működésére. 
A vizsgálatokat teljes és szegmentum májátültetéssel járó, valamint szingeneikus orthotopikus patkány 
CCA állatkísérletes májtranszplantációs modellek segítségével végeztük el. Továbbá a humán CCA 
sejtvonalból származó, valamint KMCH-1/HUCCT-1/Mz/CHA-1 és és MFB LX-2 sejteket is 
vizsgáltunk in vitro. EREDMÉNYEK. Az új klorid-koncentrációjú prezervációs oldat jótékony hatással 
volt a mikrocirkulációra a sinusoidokban és post-sinusoid venulákban javította a patkányok túlélését a 
májtranszplantációt követően. Az EPO használata serkentette a máj növekedését, mind a donorban a 
májreszekciót követően, mind a májszegment transzplantáción átesett patkányokban. Az EPO hatásai 
részben a pro-regeneratív c-jun mediátor, részben a BcL-XL anti-apoptikus gén serkentésével 
magyarázhatóak. CCA vizsgálatainkkal igazoltuk, hogy a célzott PDGFR-Beta és/vagy Hh jelátvitel 
kezelés elősegítheti a tumor-sejtek apoptózisát, az MFB-irányított PDGF-BB protektív hatás, és egy Hh 
jelátvitel-dependens folyamat gátlása révén.  Ezeken felül a PLK2-nek kiemelkedő szerepe lehet a CCA 
sejtekben Hh túlélésért felelős jelátvitelében pro-apoptikus hatásai révén. KÖVETKEZTETÉS. Az 
eredményeink jelentősen hozzájárulhatnak a májgraftok prezervációs károsodásának csökkentéséhez és 
új adatokkal szolgálnak a parciális májátültetést követő májregeneráció pontosabb megismeréséhez. 
Továbbá a tanulmányban feltárt új utak és mechanizmusok elősegíthetik a cholangiocarcinoma miatt 
végzett májátültetés indikációjának kiszélesítését és az eredmények javítását.  
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